var title_f27_26_28064="Patulous eustachian tube catheter";
var content_f27_26_28064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left patulous eustachian tube catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28064=[""].join("\n");
var outline_f27_26_28064=null;
var title_f27_26_28065="Calculator: Child Pugh classification for severity of liver disease";
var content_f27_26_28065=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"ChildPughScore_form\" name=\"ChildPughScore_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Child Pugh classification for severity of liver disease",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Encephalopathy",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         None (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Grade 1: Altered mood/confusion (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Grade 2: Inappropriate behavior, impending stupor, somnolence (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Grade 3: Markedly confused, stuporous but arousable (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Grade 4: Comatose/unresponsive (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Ascites",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Absent (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Slight (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Moderate (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Bilirubin",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         &lt; 2 mg/dL (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         2-3 mg/dL (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         &gt; 3 mg/dL (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Albumin",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         &gt; 3.5 g/dL (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         2.8-3.5 g/dL (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         &lt; 2.8 g/dL (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Prothrombin time prolongation",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than 4 seconds above control/INR &lt; 1.7 (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         4-6 seconds above control/INR 1.7-2.3 (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"ChildPughScore_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         More than 6 seconds above control/INR &gt; 2.3 (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontCCTabBold\">",
"     Total Criteria Point Count:",
"    </span>",
"    <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Child Pugh Score Interpretation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"      <tr id=\"rr1_1\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         5-6 points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Child class A",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_2\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         7-9 points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Child class B",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_3\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         10-15 points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Child class C",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <span class=\"medCalcFontOneBold\">",
"    Notes",
"   </span>",
"   <ul class=\"medCalcFontOne\">",
"    <li>",
"     In cases of Primary Biliary Cirrhosis,",
"     <b>",
"      Bilirubin",
"     </b>",
"     point values are sometimes considered differently:",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       1-4 mg/dL --&gt; 1 point",
"      </li>",
"      <li>",
"       4-10 mg/dL --&gt; 2 points",
"      </li>",
"      <li>",
"       &gt; 10 mg/dL --&gt; 3 points",
"      </li>",
"     </ul>",
"    </li>",
"    <li>",
"     Please see appropriate UpToDate topic reviews for further information.",
"    </li>",
"   </ul>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <span class=\"medCalcFontRef\">",
"    <b>",
"     References",
"    </b>",
"   </span>",
"   <ol>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      Pugh RN, Murray-Lyon IM, Dawson JL, et. al. Transection of the oesophagus for bleeding oesophageal varices.",
"      <i>",
"       Br J Surg",
"      </i>",
"      . 1973; 60:646.",
"     </span>",
"    </li>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      Child CG, Turcotte JG. The Liver and Portal Hypertension.",
"      <i>",
"       Philadelphia, WB Saunders Co",
"      </i>",
"      . 1964.",
"     </span>",
"    </li>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion.",
"      <i>",
"       NEJM",
"      </i>",
"      . 1966; 274:473.",
"     </span>",
"    </li>",
"   </ol>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    /* &lt;![CDATA[ */",
"",
";",
"ChildPughScore_fx();",
"/* ]]&gt; */",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28065=[" /* <![CDATA[ */",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function ChildPughScore_fx() {",
"with(document.ChildPughScore_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 1;",
"}",
"if (cc1[1].checked){",
"Score = Score + 2;",
"}",
"if (cc1[2].checked){",
"Score = Score + 2;",
"}",
"if (cc1[3].checked){",
"Score = Score + 3;",
"}",
"if (cc1[4].checked){",
"Score = Score + 3;",
"}",
"if (cc2[0].checked){",
"Score = Score + 1;",
"}",
"if (cc2[1].checked){",
"Score = Score + 2;",
"}",
"if (cc2[2].checked){",
"Score = Score + 3;",
"}",
"if (cc3[0].checked){",
"Score = Score + 1;",
"}",
"if (cc3[1].checked){",
"Score = Score + 2;",
"}",
"if (cc3[2].checked){",
"Score = Score + 3;",
"}",
"if (cc4[0].checked){",
"Score = Score + 1;",
"}",
"if (cc4[1].checked){",
"Score = Score + 2;",
"}",
"if (cc4[2].checked){",
"Score = Score + 3;",
"}",
"if (cc5[0].checked){",
"Score = Score + 1;",
"}",
"if (cc5[1].checked){",
"Score = Score + 2;",
"}",
"if (cc5[2].checked){",
"Score = Score + 3;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"",
"rrclr();",
"if ((Score >= 5) && (Score <= 6)){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 7) && (Score <= 9)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 10) && (Score <= 15)){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
"/* ]]> */"].join("\n");
var outline_f27_26_28065=null;
var title_f27_26_28066="Patient information: Sore throat in children (The Basics)";
var content_f27_26_28066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16967\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/28/8641\">",
"         Strep throat",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/55/18291\">",
"         Patient information: Cough, runny nose, and the common cold (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/34/8738\">",
"         Patient information: Strep throat in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/22/3427\">",
"         Patient information: Sore throat in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/44/40643\">",
"         Patient information: The common cold in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sore throat in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sore-throat-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H3295348\">",
"      <span class=\"h1\">",
"       When should I call the doctor about my child&rsquo;s sore throat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sore throat is a common problem in children. It usually gets better on its own. But sore throat can sometimes be serious.",
"     </p>",
"     <p>",
"      Call your child&rsquo;s doctor or nurse if your child has a sore throat and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Has a fever of at least 101&deg;F or 38.4&deg;C",
"       </li>",
"       <li>",
"        Doesn&rsquo;t want to eat or drink anything",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Call 9-1-1 or take your child to the emergency room if your child:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Has trouble breathing or swallowing",
"       </li>",
"       <li>",
"        Is drooling much more than usual",
"       </li>",
"       <li>",
"        Has a stiff or swollen neck",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295398\">",
"      <span class=\"h1\">",
"       What causes sore throat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sore throat is usually caused by an infection. Two types of germs can cause the infection: viruses and bacteria. Children spread germs easily because they often touch each other, share toys, and put things in their mouths.",
"     </p>",
"     <p>",
"      Children who have a sore throat caused by a virus do not usually need to see a doctor or nurse. Children who have a sore throat caused by bacteria might need to see a doctor or nurse. They might have a type of infection called strep throat. (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=see_link\">",
"       \"Patient information: Strep throat in children (The Basics)\"",
"      </a>",
"      .)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295355\">",
"      <span class=\"h1\">",
"       How can I tell if my child&rsquo;s sore throat is caused by a virus or strep throat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is hard to tell the difference. But there are some clues to look for (",
"      <a class=\"graphic graphic_figure graphicRef78761 \" href=\"UTD.htm?8/28/8641\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      People who have a sore throat caused by a virus usually have other symptoms, too. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A runny nose",
"       </li>",
"       <li>",
"        A stuffed-up chest",
"       </li>",
"       <li>",
"        Itchy or red eyes",
"       </li>",
"       <li>",
"        Cough",
"       </li>",
"       <li>",
"        A raspy (hoarse) voice",
"       </li>",
"       <li>",
"        Pain in the roof of the mouth",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who have strep throat DO NOT usually have a cough, runny nose, or itchy or red eyes.",
"     </p>",
"     <p>",
"      If you think your child might have strep throat, call your child&rsquo;s doctor. He or she can do a test to check for the bacteria that cause strep throat.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295363\">",
"      <span class=\"h1\">",
"       Does my child need antibiotics?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the sore throat is caused by a virus, your child DOES NOT need antibiotics. Unless your child has strep throat, antibiotics will NOT help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295370\">",
"      <span class=\"h1\">",
"       What can I do to help my child feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are several ways to help relieve a sore throat:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Soothing foods and drinks",
"        </strong>",
"        &ndash; Give your child things that are easy to swallow, like tea or soup, or popsicles to suck on. Your child might not feel like eating or drinking, but it&rsquo;s important that he or she gets enough liquids. Offer different warm and cold drinks for your child to try.",
"       </li>",
"       <li>",
"        <strong>",
"         Medicines",
"        </strong>",
"        &ndash;",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         Acetaminophen",
"        </a>",
"        &nbsp;(sample brand name: Tylenol&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        &nbsp;(sample brand names: Advil&reg;, Motrin&reg;) can help with throat pain. The correct dose depends on your child&rsquo;s weight, so ask your child&rsquo;s doctor how much to give.",
"        <br/>",
"        <br/>",
"        Do not give",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        or medicines that contain aspirin to children younger than 18 years. In children, aspirin can cause a serious problem called Reye syndrome. Do not give children throat sprays or cough drops, either. Throat sprays and cough drops are no better at relieving throat pain than hard candies. Plus, throat sprays can cause an allergic reaction. &nbsp;",
"       </li>",
"       <li>",
"        <strong>",
"         Other treatments",
"        </strong>",
"        &ndash; For children who are older than 3 to 4 years, sucking on hard candies or a lollipop might help. For children older than 6 to 8 years, gargling with salt water might help.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295377\">",
"      <span class=\"h1\">",
"       When can my child go back to school?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child&rsquo;s sore throat is caused by a virus, he or she should be able to go back to school as soon as he or she feels better. If your child has a fever, he or she should stay home for at least 24 hours after the fever has gone away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295384\">",
"      <span class=\"h1\">",
"       How can I keep my child from getting a sore throat again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Wash your child&rsquo;s hands often with soap and water. It is one of the best ways to prevent the spread of infection. You can use an alcohol rub instead, but make sure the hand rub gets everywhere on your child&rsquo;s hands.",
"     </p>",
"     <p>",
"      Try to teach your child about other ways to avoid spreading germs, such as not touching his or her face after being around a sick person.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3295458\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=see_link\">",
"       Patient information: Strep throat in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=see_link\">",
"       Patient information: Cough, runny nose, and the common cold (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=see_link\">",
"       Patient information: Sore throat in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40643?source=see_link\">",
"       Patient information: The common cold in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/26/28066?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16967 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-2DA2A50332-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28066=[""].join("\n");
var outline_f27_26_28066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295348\">",
"      When should I call the doctor about my child&rsquo;s sore throat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295398\">",
"      What causes sore throat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295355\">",
"      How can I tell if my child&rsquo;s sore throat is caused by a virus or strep throat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295363\">",
"      Does my child need antibiotics?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295370\">",
"      What can I do to help my child feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295377\">",
"      When can my child go back to school?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295384\">",
"      How can I keep my child from getting a sore throat again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3295458\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16967\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/28/8641\">",
"      Strep throat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=related_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=related_link\">",
"      Patient information: Sore throat in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=related_link\">",
"      Patient information: Strep throat in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40643?source=related_link\">",
"      Patient information: The common cold in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_26_28067="Occupation environment history";
var content_f27_26_28067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Systematic approach to history taking and diagnosis of occupational or environmental illness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 628px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Goldman RH, Peters JM. JAMA 1981; 246:2831.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28067=[""].join("\n");
var outline_f27_26_28067=null;
var title_f27_26_28068="Vismodegib: Patient drug information";
var content_f27_26_28068=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vismodegib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/59/18357?source=see_link\">",
"     see \"Vismodegib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13797019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Erivedge&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13769024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3638932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects.  Use a helpful kind of birth control during care and for 7 months after stopping this drug. Men must also use birth control to protect their partners from becoming pregnant. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13769025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13768981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3638877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vismodegib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13768983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3638935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not donate blood while using this drug and for 7 months after stopping.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3638943",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy during care and for 2 months after stopping this drug. Use a latex condom even if you have had a vasectomy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13769099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle or joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13768984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3644446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For men, if your woman partner gets pregnant while you are being treated or within 7 months after stopping this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13769027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take a pregnancy test before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13768982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13769100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13768985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83366 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-537ACF1ECA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28068=[""].join("\n");
var outline_f27_26_28068=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13797019\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13769024\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13769025\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768981\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768983\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13769099\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768984\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13769027\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768982\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13769100\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768985\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/59/18357?source=related_link\">",
"      Vismodegib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_26_28069="Modafinil: Patient drug information";
var content_f27_26_28069=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Modafinil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     see \"Modafinil: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/20/38214?source=see_link\">",
"     see \"Modafinil: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F197665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Provigil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alertec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2946419",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep apnea.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691979",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat narcolepsy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat shift work sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to modafinil, armodafinil, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have some heart tests before starting this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse drugs, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696707",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use some other kind of birth control while taking this drug and for 1 month after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shift work sleep problem: Take 1 hour before the start of work.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695479",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Narcolepsy: Take this drug in the morning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696499",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is near bedtime, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10873 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28069=[""].join("\n");
var outline_f27_26_28069=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197665\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197666\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020678\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020680\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020679\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020684\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020685\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020687\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020682\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020683\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020688\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020689\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=related_link\">",
"      Modafinil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/20/38214?source=related_link\">",
"      Modafinil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_26_28070="Surgery for recurrent epithelial ovarian cancer";
var content_f27_26_28070=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgery for recurrent epithelial ovarian cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28070/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28070/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28070/contributors\">",
"     Eva Chalas, MD, FACOG, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28070/contributors\">",
"     Fidel A Valea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28070/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28070/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28070/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28070/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/26/28070/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical approaches to treatment of women with recurrent epithelial ovarian cancer (EOC) are generally palliative: to prolong survival and quality of life. These procedures will be reviewed here. Second line medical therapy and initial surgical therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SECONDARY CYTOREDUCTIVE SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of ovarian cancer recurrences are within the abdomen and thus potentially amenable to cytoreductive surgery. However, the benefit of secondary cytoreduction in women with a documented or suspected recurrence of EOC is unclear because of the lack of large, randomized trials examining this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/1\">",
"     1",
"    </a>",
"    ]. Since early recurrences (ie, those with a short relapse-free interval) are often associated with a poor response to chemotherapy, the benefit of a repeat cytoreduction may be limited in this subgroup of women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon available data, secondary surgical cytoreduction is best considered only for those patients who have all of the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An extended progression-free interval of at least 12 months",
"     </li>",
"     <li>",
"      Potentially can be rendered free of all gross residual disease",
"     </li>",
"     <li>",
"      Response to first-line therapy",
"     </li>",
"     <li>",
"      Good performance status",
"     </li>",
"     <li>",
"      Locally recurrent EOC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Excision of all gross residual disease is the critical prognostic factor. Review of outcomes after secondary cytoreductive surgery showed survival of patients with optimal debulking (&le;1 cm) was 16 to 61 months versus 8 to 27 months in those with suboptimal cytoreduction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, patients who are further out from completion of their chemotherapy (&gt;12 to 36 months) are more likely to benefit from secondary cytoreduction. As an example, one study showed that survival for women who experienced a diagnosis to recurrence interval &ge;18 months was significantly longer than for those with short diagnosis to recurrence intervals (survival 49 versus 3 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/6\">",
"     6",
"    </a>",
"    ]. This study also reported improved survival in women with preoperative radiographic evidence of only 1 or 2 recurrence sites, as have others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/7\">",
"     7",
"    </a>",
"    ]. Prospective and randomized trials of the utility of secondary cytoreduction are underway (GOG 213).",
"   </p>",
"   <p>",
"    Preoperatively, it is difficult to predict whether it will be possible to achieve optimal cytoreduction. The Descriptive Evaluation of preoperative Selection KriTeria for OPerability in recurrent OVARian cancer (DESKTOP OVAR) trial (n=276 patients) found factors associated with successful surgery included good performance status, early FIGO stage initially or no residual disease after initial surgery, and absence of ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/12\">",
"     12",
"    </a>",
"    ]. A complete resection was possible in 79 percent of patients if all of these criteria were present.",
"   </p>",
"   <p>",
"    Diagnostic laparoscopy may be useful for determining whether optimal cytoreduction may be possible, or, if there is minimal disease at laparoscopy, whether placement of intraperitoneal catheter for chemotherapy is an option.",
"   </p>",
"   <p>",
"    One area of active investigation is the use of PET scanning to identify those women who may potentially benefit from this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. While PET scans alone lack sufficient anatomic resolution to evaluate precisely the feasibility of resection, combined",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    approaches show promise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. However, they are expensive and a survival benefit remains to be established. Recurrent ovarian cancer is not a Medicare-reimbursable diagnosis for PET scanning.",
"   </p>",
"   <p>",
"    On the other hand, the data regarding",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    were derived from women whose asymptomatic recurrence was detected with serial postoperative monitoring of serum CA-125. The utility of serial monitoring of CA-125 levels after initial treatment of EOC was called into question by a preliminary report of an international randomized trial which showed no survival benefit (and worse quality of life) for early institution of second-line chemotherapy based upon a raised CA-125 level alone. These data are presented and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hepatic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial hepatic resection can be performed to achieve optimal cytoreduction in women with recurrent disease confined to the liver, as well as those with both intrahepatic and extrahepatic metastases. In two series totaling 50 patients with liver involvement, the median survival after optimal cytoreduction was 27.3 and 62 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In another report of 65 patients undergoing partial hepatic resection for isolated liver metastases from ovarian cancer, the five-year survival was 50 percent, and the median survival 98 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typically, ovarian cancer spreads to the surface of the liver, rather than the parenchyma. This type of disease can be managed by the cavitron ultrasonic aspirator (CUSA), laser ablation, sharp dissection along surface of the liver, or cautery. However, when parenchymal metastasis occurs and is felt to be sufficiently limited as to make resection feasible, cautery can be used to incise the liver capsule, followed by finger fractioning and cautery dissection to excise nodules. Before beginning this type of dissection, it is helpful to divide the hepatic ligament and place one or more wet laparotomy pads below the diaphragm to displace the liver and thus improve exposure. Placement of large figure of eight sutures using a non-cutting needle assists with hemostasis, as does cautery at high settings. Gel foam pledgets or other hemostatic substances may be compressed or sutured to the liver surface. If multiple deep metastasis exist, consideration may be given to post-operative cryoablation or use of conventional or cyberknife radiotherapy for palliation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment of bowel obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel obstruction, especially involving the small intestine, is common in the setting of recurrent ovarian cancer. One autopsy study of 428 women with advanced EOC described tumor involvement of the small or large bowel in 42 and 49 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/22\">",
"     22",
"    </a>",
"    ]. Bowel obstruction in a patient with ovarian cancer may result from a combination of factors. It may be purely mechanical, with kinking or external compression of the bowel, often from adhesions, or it may be due to massive mesenteric involvement by cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of surgery as palliation for malignant bowel obstruction is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/23\">",
"     23",
"    </a>",
"    ]. Surgical procedures for patients presenting with obstruction are associated with a high morbidity and mortality, and, often, a short postoperative median survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. A literature review of approximately 700 surgeries for intestinal obstruction in women with ovarian cancer reported surgically correctable disease in 90 percent, but with major morbidity in 32 percent, perioperative death in 15 percent, and median survival of 17 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link&amp;anchor=H1142138770#H1142138770\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\", section on 'Malignant bowel obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, these patients are often malnourished and thereby, experience complications in wound healing, as confirmed by risk-adjusted outcome studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Before exploring these patients, a frank, balanced discussion of the potential benefits, the expected three to six month post-surgical recovery to baseline function, as well as the immediate and long-term complications reviewed above, must be part of informed consent. At exploration it is not always possible to resect the site of obstruction and there may be no loops free of disease to allow bypassing of the obstruction. Extensive mesenteric disease may make the entire small bowel useless for bypass. Placing a gastrotomy tube for decompression may be all that can be accomplished. Furthermore, even if the obstruction is relieved, the likelihood of reobstruction ranges from 10 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/23\">",
"     23",
"    </a>",
"    ]. Severe postoperative complications may include intestinal fistulas and anastomotic leakage.",
"   </p>",
"   <p>",
"    Nevertheless, successful palliation can be achieved surgically in a subset of women, although the identification of those women who may benefit from palliative surgery can be challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In one report of 53 women with advanced EOC and a complete bowel obstruction, successful palliation was achieved surgically in one-half, and was associated with the absence of the following four factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpable abdominal or pelvic masses",
"     </li>",
"     <li>",
"      Ascites &gt;3 liters",
"     </li>",
"     <li>",
"      Multiple obstructive sites",
"     </li>",
"     <li>",
"      Preoperative weight loss &gt;9 kg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Others have suggested that history of prior",
"    <span class=\"nowrap\">",
"     pelvic/abdominal",
"    </span>",
"    radiation is another poor prognostic factor.",
"   </p>",
"   <p>",
"    In contrast, others have failed to document specific factors associated with successful palliation. This was illustrated in a series of 64 women with bowel obstruction due to recurrent disease in whom successful surgical palliation (defined as the ability to tolerate a regular or low residue diet for at least 60 days postoperatively) was achieved in 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/26\">",
"     26",
"    </a>",
"    ]. Using logistic regression analysis, none of the following factors was found to predict successful palliation (age, initial disease stage, interval from initial diagnosis to obstruction, the presence of a palpable mass, site of obstruction, the presence or absence of systemic metastases, optimal debulking, or amount of residual disease).",
"   </p>",
"   <p>",
"    In women who are deemed not to be candidates for surgical intervention, palliative treatments can minimize terminal suffering. Percutaneous gastrostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/31\">",
"     31",
"    </a>",
"    ], adequate analgesia, intravenous hydration, and hospice care are generally of greatest benefit both to the patient and her family. Open gastrotomy may also be performed. Permanent placement of a nasogastric tube remains an option in terminal patients, recognizing patient discomfort and the risk of aspiration are significant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While most patients with cancer of the ovary present with small bowel obstruction, there are a small number with recurrence in the pelvis who present with large bowel obstruction. Diverting colostomy, either double barreled with a mucous fistula, or simple end colostomy (Hartmann's pouch) can be performed. Patients with low large bowel obstruction who are too ill for colostomy can be managed by placement of a rectal tube, either blindly or under colonoscopy guidance. Cecostomy is a last resort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ureteral obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cancer of the ovary recurs on the side wall with resulting ureteral obstruction, complete operative resection is unlikely to be possible. In these circumstances, percutaneous nephrostomy will preserve renal function, which is particularly valuable if chemotherapy with nephrotoxic agents is planned. Alternately, if the remaining kidney is functioning, no intervention is an option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TERTIARY CYTOREDUCTIVE SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are sparse data on surgical therapy of recurrent disease after secondary cytoreductive surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Even in these patients, the ability to achieve cytoreduction to no visible disease may prolong survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28070/abstract/35\">",
"     35",
"    </a>",
"    ]. However, selecting appropriate candidates for this approach, as well as the risks and benefits of surgery versus alternative therapies have not been defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"       \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"       \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10204676\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical approaches to treatment of women with recurrent epithelial ovarian cancer (EOC) are generally palliative: to prolong survival and quality of life. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of ovarian cancer recurrences are within the abdomen and thus potentially amenable to cytoreductive surgery. However, the benefit of secondary cytoreduction in women with a documented or suspected recurrence of EOC is unclear because of the lack of large, randomized trials examining this issue. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Secondary cytoreductive surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based upon available data, secondary surgical cytoreduction is best considered only for those patients who have all of the following characteristics: extended progression-free interval of at least 12 months; potentially can be rendered free of all gross residual disease; response to first-line therapy; good performance status; locally recurrent EOC. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of surgery as palliation for malignant bowel obstruction is controversial. Surgical procedures for patients presenting with obstruction are associated with a high morbidity and mortality, and, often, a short postoperative median survival. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment of bowel obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When cancer of the ovary recurs on the side wall with resulting ureteral obstruction, complete operative resection is unlikely to be possible. In these circumstances, percutaneous nephrostomy will preserve renal function, which is particularly valuable if chemotherapy with nephrotoxic agents is planned. Alternately, if the remaining kidney is functioning, no intervention is an option. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ureteral obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are sparse data on surgical therapy of recurrent disease after secondary cytoreductive surgery. Even in these patients, the ability to achieve cytoreduction to no visible disease may prolong survival. However, selecting appropriate candidates for this approach, as well as the risks and benefits of surgery versus alternative therapies have not been defined. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Tertiary cytoreductive surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/1\">",
"      Park JY, Eom JM, Kim DY, et al. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer. J Surg Oncol 2010; 101:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/2\">",
"      Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 2004; 95:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/3\">",
"      G&uuml;ng&ouml;r M, Orta&ccedil; F, Arvas M, et al. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol 2005; 97:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/4\">",
"      Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 2005; 92:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/5\">",
"      Berek JS, Bertelsen K, du Bois A, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10 Suppl 1:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/6\">",
"      Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 2007; 109:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/7\">",
"      Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/8\">",
"      Tebes SJ, Sayer RA, Palmer JM, et al. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2007; 106:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/9\">",
"      Benedetti Panici P, De Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 2007; 14:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/10\">",
"      Santillan A, Karam AK, Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 2007; 104:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/11\">",
"      Tian WJ, Jiang R, Cheng X, et al. Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. J Surg Oncol 2010; 101:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/12\">",
"      Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/13\">",
"      Cho SM, Ha HK, Byun JY, et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol 2002; 179:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/14\">",
"      Yen RF, Sun SS, Shen YY, et al. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001; 21:3691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/15\">",
"      Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003; 90:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/16\">",
"      Makhija S, Howden N, Edwards R, et al. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002; 85:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/17\">",
"      Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007; 105:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/18\">",
"      Soussan M, Wartski M, Cherel P, et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 2008; 108:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/19\">",
"      Yoon SS, Jarnagin WR, Fong Y, et al. Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecol Oncol 2003; 91:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/20\">",
"      Merideth MA, Cliby WA, Keeney GL, et al. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol 2003; 89:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/21\">",
"      Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006; 244:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/22\">",
"      Rose PG, Piver MS, Tsukada Y, Lau TS. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 1989; 64:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/23\">",
"      Feuer DJ, Broadley KE, Shepherd JH, Barton DP. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev 2000; :CD002764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/24\">",
"      Chalas E, Mann WJ Jr, Westermann CP, Patsner B. Morbidity and mortality of stapled anastomoses on a gynecologic oncology service: a retrospective review. Gynecol Oncol 1990; 37:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/25\">",
"      Coukos G, Rubin SC. Surgical management of epithelial ovarian cancer. Oncology Spectrums 2001; 2:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/26\">",
"      Pothuri B, Vaidya A, Aghajanian C, et al. Palliative surgery for bowel obstruction in recurrent ovarian cancer:an updated series. Gynecol Oncol 2003; 89:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/27\">",
"      Fink AS, Hutter MM, Campbell DC Jr, et al. Comparison of risk-adjusted 30-day postoperative mortality and morbidity in Department of Veterans Affairs hospitals and selected university medical centers: general surgical operations in women. J Am Coll Surg 2007; 204:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/28\">",
"      Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993; 71:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/29\">",
"      Tamussino KF, Lim PC, Webb MJ, et al. Gastrointestinal surgery in patients with ovarian cancer. Gynecol Oncol 2001; 80:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/30\">",
"      Jong P, Sturgeon J, Jamieson CG. Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer. Can J Surg 1995; 38:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/31\">",
"      Pothuri B, Montemarano M, Gerardi M, et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 2005; 96:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/32\">",
"      Leitao MM Jr, Kardos S, Barakat RR, Chi DS. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol 2004; 95:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/33\">",
"      Karam AK, Santillan A, Bristow RE, et al. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol 2007; 104:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/34\">",
"      Shih KK, Chi DS, Barakat RR, Leitao MM Jr. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 2010; 116:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28070/abstract/35\">",
"      Shih KK, Chi DS, Barakat RR, Leitao MM Jr. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol 2010; 117:330.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3196 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28070=[""].join("\n");
var outline_f27_26_28070=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10204676\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SECONDARY CYTOREDUCTIVE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hepatic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment of bowel obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ureteral obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TERTIARY CYTOREDUCTIVE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10204676\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=related_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=related_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_26_28071="All trans retinoic acid (tretinoin): Pediatric drug information";
var content_f27_26_28071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   All trans retinoic acid (tretinoin): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/22/29032?source=see_link\">",
"    see \"All trans retinoic acid (tretinoin): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/51/30517?source=see_link\">",
"    see \"All trans retinoic acid (tretinoin): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vesanoid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1040438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Retinoic Acid Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1040469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/22/29032?source=see_link\">",
"      see \"All trans retinoic acid (tretinoin): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (refer to individual protocols):",
"     <b>",
"      Note:",
"     </b>",
"     Induction treatment of APL with tretinoin should be initiated early; discontinue if pending cytogenetic analysis does not confirm t(15;17) translocation or the presence of the PML/RAR&alpha; fusion protein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acute promyelocytic leukemia (APL):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Limited data available (de Botton, 2004; Gregory, 2009; Mann, 2001; Ortega, 2005; Sanz, 2009; Testi, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Remission induction: 45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in two equally divided doses until documentation of complete remission (CR); discontinue after CR or after 90 days of treatment, whichever occurs first",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Remission induction (in combination with an anthracycline): 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in two equally divided doses until complete remission or 90 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Consolidation therapy, intermediate- and high-risk patients: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in two equally divided doses for 15 days each month for 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance therapy, intermediate- and high-risk patients: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in two equally divided doses for 15 days every 3 months for 2 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Remission induction: 45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in two equally divided doses until documentation of complete remission (CR); discontinue 30 days after CR or after 90 days of treatment, whichever occurs first",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Remission induction (in combination with an anthracycline): 45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in two equally divided doses until complete remission or 90 days (Sanz, 2004; Sanz, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Consolidation therapy, intermediate- and high-risk patients: 45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in two equally divided doses for 15 days each month for 3 months (Sanz, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance therapy, intermediate- and high-risk patients: 45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in two equally divided doses for 15 days every 3 months for 2 years (Sanz, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1040474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with a meal; do not crush capsules.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     It is not recommended to use the capsule contents to extemporaneously prepare tretinoin suspension; however, there are limited case reports of use in patients who are unable to swallow the capsules whole. In a patient with a nasogastric (NG) tube, tretinoin capsules were cut open, with partial aspiration of the contents into a glass syringe, the residual capsule contents were mixed with soy bean oil and aspirated into the same syringe and administered (Shaw, 1995). Tretinoin capsules have also been mixed with sterile water (~20 mL) and heated in a water bath (37&deg;C) to melt the capsules and create an oily suspension for NG tube administration (Bargetzi, 1996). Tretinoin has also been administered sublingually by squeezing the capsule contents beneath the tongue (Kueh, 1999). Low plasma levels have been reported when contents of tretinoin capsules were administered directly through a feeding tube, although patient-specific impaired absorption may have been a contributing factor (Takitani, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1040459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1040439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction of remission in patients with acute promyelocytic leukemia (APL), French American British (FAB) classification M3 (including the M3 variant) characterized by t(15;17) translocation and/or PML/RAR&alpha; gene presence (FDA approved in adults); has also been used in post consolidation and maintenance therapy in APL and combination therapy (with arsenic trioxide) for remission induction in APL",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16254058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tretinoin may be confused with ISOtretinoin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tretinoin (which is also called all-",
"       <i>",
"        trans",
"       </i>",
"       retinoic acid, or ATRA) may be confused with isotretinoin; while both products may have uses in cancer treatment, they are",
"       <b>",
"        not",
"       </b>",
"       interchangeable.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F230451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most patients will experience drug-related toxicity, especially headache, fever, weakness and fatigue. These are seldom permanent or irreversible and do not typically require therapy interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, cardiac arrest, cardiac failure, cardiomyopathy, chest discomfort, cerebral hemorrhage, edema, facial edema, flushing, heart enlarged, heart murmur, hyper-/hypotension, ischemia, MI, myocarditis, pallor, pericarditis, peripheral edema, secondary cardiomyopathy, stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, aphasia, cerebellar edema, CNS depression, coma, confusion, dementia, depression, dizziness, encephalopathy, facial paralysis, fever, forgetfulness, hallucination, headache, hypotaxia, hypothermia, insomnia, Intracranial hypertension, light reflex absent, malaise, pain, seizure, slow speech, somnolence, spinal cord disorder, unconsciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, cellulitis, pruritus, rash, skin changes, skin/mucous membrane dryness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, fluid imbalance, hypercholesterolemia and/or hypertriglyceridemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, abdominal pain, anorexia, constipation, diarrhea, dyspepsia, GI hemorrhage, hepatitis, hepatosplenomegaly, liver function tests increased, mucositis, nausea/vomiting, ulcer, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, micturition frequency, prostate enlarged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Disseminated intravascular coagulation, hemorrhage, leukocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Ascites, hepatitis, liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, asterixis, bone inflammation, bone pain, dysarthria, flank pain, hemiplegia hyporeflexia leg weakness, myalgia, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Agnosia, ocular disorder, visual acuity change, visual disturbance, visual field deficit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Earache/ear fullness, hearing loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, renal insufficiency, renal tubular necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchial asthma, dyspnea, expiratory wheezing, larynx edema, lower respiratory tract disorders, pleural effusion, pneumonia, pulmonary hypertension, pulmonary infiltration, rales, respiratory insufficiency, upper respiratory tract disorders",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, infection, lymph disorder, shivering, retinoic acid-acute promyelocytic leukemia syndrome/differentiation syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Arterial thrombosis, basophilia, erythema nodosum, genital ulceration, hypercalcemia, hyperhistaminemia, irreversible hearing loss, myositis, organomegaly, pancreatitis, pseudotumor cerebri, renal infarct, Sweet's syndrome, thrombocytosis, vasculitis (skin), venous thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1040444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tretinoin, other retinoids, parabens, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9728480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. The risk for thrombosis (arterial and venous) is increased during the first month of treatment. Use with caution with antifibrinolytic agents (eg, tranexamic acid, aminocaproic acid, aprotinin); thrombotic complications have been reported (rarely) with concomitant use. May cause headache, malaise, and/or dizziness; caution patients about performing tasks which require mental alertness (eg, operating machinery or driving). Avoid additional vitamin A supplementation; may lead to vitamin A toxicity. Tretinoin should only be administered under the supervision of a physician who is experienced in the management of patients with acute leukemia, including assessment of possible benefit outweighing risks of known adverse effects",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1040445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     About 25% of patients with APL treated with tretinoin have experienced APL differentiation syndrome (DS); formerly called retinoic acid-APL [RA-APL] syndrome, which is characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, and pleural or pericardial effusions, edema, and hepatic, renal, and/or multiorgan failure",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . DS usually occurs during the first month of treatment with some cases reported following the first dose. DS has been observed with or without concomitant leukocytosis and has occasionally been accompanied by impaired myocardial contractility and episodic hypotension. Endotracheal intubation and mechanical ventilation have been required in some cases due to progressive hypoxemia and several patients have expired with multiorgan failure. About one half of DS cases are severe, which is associated with increased mortality. Management has not been defined, although high-dose steroids given at the first suspicion appear to reduce morbidity and mortality. Regardless of the leukocyte count, at the first signs suggestive of DS, immediately initiate steroid therapy with dexamethasone (10 mg I.V. every 12 hours for 3-5 days); taper off over 2 weeks. Most patients do not require termination of tretinoin therapy during treatment of DS.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     During treatment, ~40% of patients will develop rapidly evolving leukocytosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . A high WBC at diagnosis increases the risk for further leukocytosis and may be associated with a higher risk of life-threatening complications. If signs and symptoms of the APL-DS syndrome are present together with leukocytosis, initiate treatment with high-dose steroids immediately. Consider adding full-dose chemotherapy (including an anthracycline if not contraindicated) to the tretinoin therapy on day 1 or 2 for patients presenting with a WBC count of &gt;5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L; or start immediately if WBC is &lt;5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L at presentation or reaches &ge;6 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L by day 5 or &ge;10 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L by day 10 or &ge;15 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L by day 28.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Retinoids have been associated with pseudotumor cerebri (benign intracranial hypertension), especially in children. Concurrent use of other drugs associated with this effect (eg, tetracyclines) may increase risk. Early signs and symptoms include papilledema, headache, nausea, vomiting, visual disturbances, intracranial noises, or pulsate tinnitus.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     There is a high risk of teratogenicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .  Increased risk of spontaneous abortion and major fetal abnormalities have been reported with use of other retinoids. If treatment with tretinoin is required in women of childbearing potential, two reliable forms of contraception should be used during and for 1 month after treatment. Microdosed progesterone preparations (eg, \"minipill\") may be inadequate during tretinoin treatment. Pregnancy testing and contraception counseling should be repeated monthly throughout the period of treatment. If possible, initiation of treatment with tretinoin should be delayed until negative pregnancy test result is confirmed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Tretinoin treatment for APL should be initiated early; discontinue and consider alternate therapy if pending cytogenetic analysis does not confirm APL by t(15;17) translocation or the presence of the PML/RAR&alpha; fusion protein (caused by translocation of the promyelocytic [PML] gene on chromosome 15 and retinoic acid receptor [RAR] alpha gene on chromosome 17).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypercholesterolemia and hypertriglyceridemia have been reported in up to 60% of patients, which was reversible upon completion of treatment. Elevated liver function test results occur in 50% to 60% of patients during treatment. Carefully monitor liver function test results during treatment and give consideration to a temporary withdrawal of tretinoin if test results reach &gt;5 times the upper limit of normal. Most liver function test abnormalities will resolve without interruption of treatment or after therapy completion.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F230441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (minor), CYP2B6 (minor), CYP2C8 (major), CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2E1 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifibrinolytic Agents: Tretinoin (Systemic) may enhance the thrombogenic effect of Antifibrinolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin A: Retinoic Acid Derivatives may enhance the adverse/toxic effect of Vitamin A.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1040458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     The absorption of retinoids (as a class) is enhanced when taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F230413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: High risk of teratogenicity; if treatment with tretinoin is required  in women of childbearing potential, two reliable forms of contraception should be used during and for 1 month after treatment.",
"     </b>",
"     Within 1 week prior to starting therapy, serum or urine pregnancy test (sensitivity 50 mIU/mL) should be collected. If possible, delay therapy until results are available. Repeat pregnancy testing and contraception counseling monthly throughout the period of treatment. An increase in fetal resorptions and a decrease in live fetuses were observed in all animal reproduction studies; teratogenic effects have also been observed. Use in humans is limited, however, major fetal abnormalities and spontaneous abortions have been reported with other retinoids. If the clinical condition of a patient presenting with APL during pregnancy warrants immediate treatment, tretinoin use should be avoided in the first trimester; treatment with tretinoin may be considered in the second and third trimester with careful fetal cardiac monitoring.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1040476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bone marrow cytology to confirm t(15;17) translocation or the presence of the PML/RAR&alpha; fusion protein (do not withhold treatment initiation for results); monitor CBC with differential, coagulation profile, liver function test results, and triglyceride and cholesterol levels frequently; monitor closely for signs of APL differentiation syndrome (eg, monitor volume status, pulmonary status, temperature, respiration)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1040461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tretinoin appears to bind one or more nuclear receptors and decrease proliferation and induce differentiation of APL cells; initially producing maturation of primitive promyelocytes and repopulation of the marrow and peripheral blood with normal hematopoietic cells to achieve complete remission.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1040463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reported pediatric values similar to adult (Smith, 1992; Takitani, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well-absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;95%, predominantly to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP; primary metabolite: 4-oxo-all-",
"     <i>",
"      trans",
"     </i>",
"     -retinoic acid; displays autometabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (63%); feces (30%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1040480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/51/30517?source=see_link\">",
"      see \"All trans retinoic acid (tretinoin): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by prescriber. Take with food. Do not crush, chew, or dissolve capsules. Maintain adequate hydration unless instructed to restrict fluid intake. Avoid alcohol and foods containing vitamin A, as well as foods with high fat content. May cause lethargy, dizziness, visual changes, confusion, and anxiety (avoid driving or engaging in tasks requiring alertness until response to drug is known); nausea, vomiting, loss of appetite, or dry mouth (small, frequent meals, chewing gum, or sucking lozenges may help); photosensitivity (use sunscreen, wear protective clothing and eyewear, and avoid direct sunlight); dry, itchy skin; or dry or irritated eyes (avoid contact lenses). Report persistent vomiting or diarrhea, respiratory difficulty, unusual bleeding or bruising, acute GI pain, bone pain, swelling of extremities, unusual weight gain, or vision changes immediately.",
"     <b>",
"      Pregnancy/Breast-Feeding Precautions:",
"     </b>",
"     Do not get pregnant (females) or cause a pregnancy (males) while taking this medication and for 1 month following completion of therapy. Consult prescriber for appropriate barrier contraceptive measures if necessary or if you suspect you might be pregnant. This drug should not be used in the first trimester of pregnancy. Breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F9728481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For management of APL differentiation syndrome, initiate at first signs of DS: Dexamethasone 10 mg I.V. every 12 hours for 3-5 days; consider interrupting tretinoin until resolution of hypoxia",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F8771505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Although the manufacturer does not recommend the use of the capsule contents to extemporaneously prepare a suspension of tretinoin (due to reports of low plasma levels) (Vesanoid&reg; data on file), there are limited case reports of use in patients who are unable to swallow the capsules whole. In a patient with a nasogastric (NG) tube, tretinoin capsules were cut open, with partial aspiration of the contents aspirated into a glass syringe. The residual capsule contents were mixed with soybean oil, aspirated into the syringe, and administered (Shaw, 1995). Tretinoin capsules have also been mixed with sterile water (~20 mL) and heated in a water bath to melt the capsules and create an oily suspension for NG tube administration (Bargetzi, 1996). Tretinoin has also been administered sublingually by squeezing the capsule contents beneath the tongue (Kueh, 1999).",
"    </p>",
"    <div class=\"reference\">",
"     Bargetzi MJ, Tichelli A, Gratwohl A, et al, \"Oral All-Transretinoic Acid Administration in Intubated Patients With Acute Promyelocytic Leukemia,\"",
"     <i>",
"      Schweiz Med Wochenschr",
"     </i>",
"     , 1996, 126(45):1944-5.",
"     <span class=\"pubmed-id\">",
"      8946598",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Kueh YK, Liew PP, Ho PC, et al, \"Sublingual Administration of All-",
"     <i>",
"      Trans",
"     </i>",
"     -Retinoic Acid to a Comatose Patient With Acute Promyelocytic Leukemia,\"",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 1999, 33(4):503-5.",
"     <span class=\"pubmed-id\">",
"      10332546",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Shaw PJ, Atkins MC, Nath CE, et al, \"ATRA Administration in the Critically Ill Patient,\"",
"     <i>",
"      Leukemia",
"     </i>",
"     , 1995, 9(7):1288.",
"     <span class=\"pubmed-id\">",
"      7630206",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Vesanoid&reg; data on file, Roche Pharmaceuticals",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bargetzi MJ, Tichelli A, Gratwohl A, et al, \"Oral All-transretinoic Acid Administration in Intubated Patients With Acute Promyelocytic Leukemia,\"",
"      <i>",
"       Schweiz Med Wochenschr",
"      </i>",
"      , 1996, 126(45):1944-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/8946598/pubmed\" id=\"8946598\" target=\"_blank\">",
"        8946598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Botton S, Coiteux V, Chevret S, et al, \"Outcome of Childhood Acute Promyelocytic Leukemia With All-",
"      <i>",
"       Trans",
"      </i>",
"      -Retinoic Acid and Chemotherapy,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(8):1404-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/15084614/pubmed\" id=\"15084614\" target=\"_blank\">",
"        15084614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gregory J, Kim H, Alonzo T, et al, \"Treatment of Children With Acute Promyelocytic Leukemia: Results of the First North American Intergroup Trial INT0129,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(6):1005-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/19743516/pubmed\" id=\"19743516\" target=\"_blank\">",
"        19743516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kueh YK, Liew PP, Ho PC, et al, \"Sublingual Administration of All-",
"      <i>",
"       Trans",
"      </i>",
"      -retinoic Acid to a Comatose Patient With Acute Promyelocytic Leukemia,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):503-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/10332546/pubmed\" id=\"10332546\" target=\"_blank\">",
"        10332546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mann G, Reinhardt D, Ritter J, et al, \"Treatment With All-trans Retinoic Acid in Acute Promyelocytic Leukemia Reduces Early Deaths in Children,\"",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 2001, 80(7):417-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/11529468/pubmed\" id=\"11529468\" target=\"_blank\">",
"        11529468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Acute Myeloid Leukemia,&rdquo; Version 1, 2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/aml.pdf.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ortega JJ, Madero L, Mart&iacute;n G, et al, \"Treatment With All-",
"      <i>",
"       trans",
"      </i>",
"      Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7632-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/16234524/pubmed\" id=\"16234524\" target=\"_blank\">",
"        16234524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Grimwade D, Tallman MS, et al, \"Management of Acute Promyelocytic Leukemia: Recommendations From an Expert Panel on Behalf of the European LeukemiaNet,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 113(9):1875-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/18812465/pubmed\" id=\"18812465\" target=\"_blank\">",
"        18812465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Mart&iacute;n G, Gonz&aacute;lez M, et al, \"Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-",
"      <i>",
"       trans",
"      </i>",
"      -retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(4):1237-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/14576047/pubmed\" id=\"14576047\" target=\"_blank\">",
"        14576047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanz MA, Montesinos P, Vellenga E, et al, \"Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-",
"      <i>",
"       trans",
"      </i>",
"      Retinoic Acid and Anthracycline Monochemotherapy: Long-Term Outcome of the LPA 99 Multicenter Study by the PETHEMA Group,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(8):3130-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/18664623/pubmed\" id=\"18664623\" target=\"_blank\">",
"        18664623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaw PJ, Atkins MC, Nath CE, et al, \"ATRA Administration in the Critically Ill Patient,\"",
"      <i>",
"       Leukemia",
"      </i>",
"      , 1995, 9(7):1288.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/7630206/pubmed\" id=\"7630206\" target=\"_blank\">",
"        7630206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Takitani K, Koh M, Inoue A, et al, \"Pharmacokinetics of All-",
"      <i>",
"       Trans",
"      </i>",
"      Retinoic Acid in Adults and Children With Acute Promyelocytic Leukemia,\"",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 2006, 81(9):720-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/16838336/pubmed\" id=\"16838336\" target=\"_blank\">",
"        16838336",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Takitani K, Nakao Y, Kosaka Y, et al, \"Low Plasma Level of All-",
"      <i>",
"       trans",
"      </i>",
"      Retinoic Acid After Feeding Tube Administration for Acute Promyelocytic Leukemia,\"",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 2004, 76(1):97-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/15114613/pubmed\" id=\"15114613\" target=\"_blank\">",
"        15114613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Testi AM, Biondi A, Lo Coco F, et al, \"GIMEMA-AIEOPAIDA Protocol for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in Children,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 106(2):447-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/26/28071/abstract-text/15677559/pubmed\" id=\"15677559\" target=\"_blank\">",
"        15677559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vesanoid&reg; data on file, Roche Pharmaceuticals.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13099 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28071=[""].join("\n");
var outline_f27_26_28071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708896\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230427\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040438\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040469\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230404\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230389\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040474\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040459\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040439\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16254058\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230451\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040444\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728480\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040445\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230441\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230398\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040458\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230400\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230413\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040476\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040461\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040463\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1040480\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9728481\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8771505\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13099\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13099|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/22/29032?source=related_link\">",
"      All trans retinoic acid (tretinoin): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/51/30517?source=related_link\">",
"      All trans retinoic acid (tretinoin): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_26_28072="Basic approach to arrhythmias due to digoxin toxicity";
var content_f27_26_28072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic approach to arrhythmias due to digoxin toxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28072/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28072/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28072/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28072/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28072/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28072/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/26/28072/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac glycosides (digitalis preparations including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and digitoxin) are used clinically in two situations: heart failure due to systolic dysfunction, and in certain supraventricular tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ability to enhance cardiac contractility and modulate neurohumoral activation can lead to symptomatic improvement in systolic heart failure, although it is unclear if survival is prolonged. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"       \"Use of digoxin in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      also slows conduction through the atrioventricular (AV) junction (node) by increasing vagal tone. It may also have a sympathoinhibitory effect in therapeutic doses. As a result, it is sometimes used (usually adjunctively with beta blockers or calcium channel blockers) for controlling the ventricular response in atrial fibrillation and atrial flutter when there is excessively rapid transmission of stimuli from the atria to the ventricles through the AV junction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"       \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=see_link\">",
"       \"Control of ventricular rate in atrial flutter\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      may also be effective in the treatment of certain types of reentrant paroxysmal supraventricular tachycardia involving the AV node.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    toxicity is an important clinical problem which may be life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence of digoxin excess and toxicity, along with the potential associated arrhythmias, are presented here. The management of digoxin intoxication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link\">",
"     \"Digitalis (cardiac glycoside) poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE OF DIGOXIN TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technical advances and changes in practice patterns have lowered the incidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    overdose in patients receiving chronic therapy. However, digoxin toxicity remains an important clinical syndrome in which potentially fatal cardiac arrhythmias can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large study of patients with congestive heart failure who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , definite digoxin toxicity occurred in 0.8 percent and possible toxicity in another 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/4\">",
"     4",
"    </a>",
"    ]. This incidence is lower than had been seen historically, an improvement thought to result from several changes in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      in place of digitoxin and other digitalis preparations.",
"     </li>",
"     <li>",
"      A better understanding of pharmacokinetics, leading to more appropriate maintenance dosing, particularly in patients with renal failure.",
"     </li>",
"     <li>",
"      Improvement in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      formulations with more predictable drug bioavailability.",
"     </li>",
"     <li>",
"      The development of accurate radioimmunoassays for plasma",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      levels [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The availability of other drugs to treat chronic heart failure (eg, angiotensin converting enzyme inhibitors and beta blockers) and cardiac arrhythmias (calcium channel blockers and beta blockers for rate control in atrial fibrillation), thereby minimizing the tendency to \"push\"",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      to higher and potentially more toxic levels.",
"     </li>",
"     <li>",
"      The development of catheter ablation therapies for supraventricular tachyarrhythmias and of cardiac resynchronization therapy for heart failure.",
"     </li>",
"     <li>",
"      Increased appreciation of factors that can increase the risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      intoxication such as renal insufficiency, electrolyte abnormalities (hypokalemia, hypomagnesemia and hypercalcemia), acute myocardial ischemia, advanced age, hypothyroidism, pulmonary disease, and pharmacokinetic interactions with other drugs that can affect digoxin metabolism. Included in this group are drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , which may raise digoxin levels at least in part by reducing its excretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, despite these factors, there is a suggestion that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity may again be on the rise, having been found in 4 percent of patients in a 1998 study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Plasma digoxin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-threatening",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -induced arrhythmias and other toxic manifestations occur at substantially increasing frequency, especially as the plasma digoxin concentration rises above 2.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    However, clinicians should be aware that signs of toxicity may occur at levels below 1.3 to 1.5",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and such toxicity is more likely in the presence of one or more of the predisposing factors noted above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link\">",
"     \"Digitalis (cardiac glycoside) poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypokalemia is a particularly important risk factor that can promote",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -induced arrhythmias even if the digoxin concentration is well within the \"therapeutic\" range. Retrospective analysis of data from the large digitalis investigation group (DIG trial) revealed that serum digoxin levels ranging from 1.2 to 2.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    were associated with an excess mortality versus placebo in women with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, we recommend maintaining trough",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    levels at the lower range (eg, between 0.5 and 0.8",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    in both male and female patients to help minimize toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    levels should be measured at least 6 hours and preferably 12 or more hours after the last dose since this is the time required for attainment of the steady state due to gradual distribution through the extravascular space. Measurements made sooner after ingestion may give values two to three times higher, because equilibration has not occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISMS OF CARDIAC TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism(s) by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity promotes the development of arrhythmias remain incompletely understood. Two general categories have been described&mdash;enhanced ectopy with tachyarrhythmias, and bradyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/5\">",
"     5",
"    </a>",
"    ]. Digoxin can affect cardiac tissue in a number of ways which may result in toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      directly inhibits the ATPase dependent sodium-potassium pump, increasing intracellular sodium. This, in turn, reduces the activity of a sodium-calcium exchanger that normally extrudes calcium from the cell [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/10\">",
"       10",
"      </a>",
"      ]. The resulting increase in intracellular calcium is responsible for the positive inotropic action of digoxin. The fluxes in calcium can also have electrophysiologic effects.",
"     </li>",
"     <li>",
"      Nanomolar concentrations of cardiac glycosides can alter the ion selectivity of voltage-sensitive sodium channels in sarcolemmal and T-tubular membranes, permitting calcium entry by a mechanism termed \"slip-mode conductance\" [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/11\">",
"       11",
"      </a>",
"      ]. However, the importance of this effect to drug action is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac glycosides activate ryanodine receptors, which could contribute to increased calcium release from the sarcoplasmic reticulum and could play a role in the inotropic action of glycosides in vivo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      increases vagal tone through central and peripheral effects [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      has been shown to increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in murine viral myocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/14\">",
"       14",
"      </a>",
"      ]. The precise effect of this on potential digoxin toxicity remains undefined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of the effect on intracellular calcium concentrations and vagal tone, high levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    can have a variety of effects that facilitate the development of arrhythmias. They can enhance and depress automaticity, induce triggered membrane activity (especially delayed afterdepolarizations), increase or decrease excitability, slow conduction, and alter refractoriness, also producing conditions conducive to the development of reentrant arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13658052\">",
"    <span class=\"h1\">",
"     DIGOXIN-INDUCED ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost any arrhythmia occurring at almost any intracardiac location can be seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity, depending in part upon the age of the patient and the state of the myocardium. Accentuation of vagal effects and resulting bradyarrhythmias is more commonly seen in younger, healthier individuals. Conversely, patients with severe cardiac disease and concurrent digoxin toxicity are more susceptible to ventricular ectopy and tachyarrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=see_link&amp;anchor=H9#H9\">",
"     \"ECG tutorial: Miscellaneous diagnoses\", section on 'Digitalis toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, some arrhythmias that are generally not induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    . Atrial flutter, atrial fibrillation, and Mobitz type II second degree AV block are the least&nbsp;likely of all the arrhythmias to be caused by digoxin toxicity. However, superimposed digoxin toxicity may occur in these settings, for example leading to an excessively slow or regularized ventricular response in atrial fibrillation.",
"   </p>",
"   <p>",
"    The arrhythmias associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity will be discussed according to their myocardial site of origin, including the sinoatrial nodal tissue, atrial myocardium, atrioventricular nodal tissue, and ventricular myocardium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13658144\">",
"    <span class=\"h2\">",
"     Sinus bradycardia, tachycardia, block, and arrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and digoxin toxicity on the SA node is often difficult to determine because of both indirect and direct actions. As an example, improved hemodynamics in heart failure usually result in a fall in heart rate due to alterations in autonomic balance. Alternatively, sinus bradycardia may also be one of the earliest signs of digoxin excess.",
"   </p>",
"   <p>",
"    Cardiac glycosides have no direct effect on slowing automaticity in the isolated SA node or in the transplanted human heart [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, the diseased SA node may be quite sensitive to cardiac glycosides, resulting in sinus bradycardia and SA nodal block [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/4,17-19\">",
"     4,17-19",
"    </a>",
"    ]. Animal and human studies suggest that the slowing of the heart rate in this setting is due both to increased vagal tone (mediated by hypersensitization of carotid sinus baroreceptors, central stimulation, increased vagal traffic, and possible potentiation of the effect of acetylcholine on the SA node) and to sympatholytic activity.",
"   </p>",
"   <p>",
"    While most commonly sinus bradycardia is seen, the sinus pacemaker may accelerate in the presence of excess",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    . Both adrenergic stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/15,20-22\">",
"     15,20-22",
"    </a>",
"    ] and direct stimulation of the pacemaker may contribute to this response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxic levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    can also result in SA nodal block (",
"    <a class=\"graphic graphic_waveform graphicRef68081 graphicRef54936 \" href=\"UTD.htm?30/24/31113\">",
"     waveform 1A-B",
"    </a>",
"    ) or even nodal arrest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38756?source=see_link\">",
"     \"Sinoatrial nodal pause, arrest, and exit block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13658391\">",
"    <span class=\"h2\">",
"     Ectopic atrial tachycardia with block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    have little effect on atrial tissue, but toxic levels may result in an ectopic atrial tachycardia, often with 2:1 AV block. Animal studies suggest that the atrial tachycardia is probably mediated by increased automaticity in the atrium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delayed afterpotentials, often occurring near and perhaps sometimes within the SA node [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/24,26,27\">",
"     24,26,27",
"    </a>",
"    ]. The AV block probably results from the rapid atrial rate, as well as the vagotonic activity and a direct effect of digoxin on AV nodal conduction (see below).",
"   </p>",
"   <p>",
"    Also referred to as &ldquo;paroxysmal&rdquo; atrial tachycardia, this arrhythmia is strongly suggestive of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity. However, the arrhythmia is typically not paroxysmal when induced by digoxin; rather, it is a persistent arrhythmia until specific therapy is instituted or digoxin levels fall below the toxic range. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=see_link&amp;anchor=H15#H15\">",
"     \"Focal atrial tachycardia\", section on 'Treatment'",
"    </a>",
"    .) It should be noted that most cases of atrial tachycardia with block are not due to digoxin excess in contemporary practice.",
"   </p>",
"   <p>",
"    Clinically, up to one-half of patients with nonparoxysmal atrial tachycardia with AV nodal block have a P wave morphology similar to the sinus P wave (",
"    <a class=\"graphic graphic_waveform graphicRef56994 \" href=\"UTD.htm?41/17/42262\">",
"     waveform 2",
"    </a>",
"    ). This observation supports the suggestion in animal studies that the ectopic site is often near, or is perhaps in, the SA node. The remaining cases arise at other sites and typically have an abnormal P wave axis as seen in the ectopic atrial tachycardias.",
"   </p>",
"   <p>",
"    Atrial tachycardia with block may superficially resemble atrial flutter. There are two major distinguishing features between these arrhythmias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The atrial rate is faster (usually 250 to 350",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      with atrial flutter.",
"     </li>",
"     <li>",
"      The baseline between P waves is isoelectric in atrial tachycardia with block, while there is a constantly undulating baseline between the flutter waves in atrial flutter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to distinguish between atrial flutter and atrial tachycardia due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    excess since the administration of additional digoxin, which may be an appropriate therapy for atrial flutter, can accelerate the atrial rate in an atrial tachycardia, increasing the degree of AV block and potentially precipitating a more serious digoxin-toxic arrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13658508\">",
"    <span class=\"h2\">",
"     Atrial fibrillation and flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    toxicity can occur in patients with atrial fibrillation or flutter, even though these arrhythmias are rarely caused by digoxin. A more important clinical problem is the effect of digoxin toxicity on transmission of atrial stimuli through the AV node in patients with preexisting atrial fibrillation. The electrocardiographic findings vary with increasing degrees of digoxin toxicity and with the possible presence of block above or below the pacemaker (",
"    <a class=\"graphic graphic_waveform graphicRef64396 graphicRef76154 graphicRef55119 graphicRef66940 \" href=\"UTD.htm?42/7/43130\">",
"     waveform 3A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/28\">",
"     28",
"    </a>",
"    ]. Casual evaluation of such a patient who might have severe digoxin toxicity may lead to the mistaken conclusion that the irregular rhythm is due to persistent AF and the digoxin may be inappropriately continued or the dose even increased.",
"   </p>",
"   <p>",
"    Atrial flutter is rarely, if ever, the result of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    intoxication. However, the diagnosis of atrial flutter may be difficult to establish when, as commonly occurs during digoxin therapy, the atrial flutter has a slow ventricular response, with a rate that overlaps that seen in other supraventricular tachycardias, such as nonparoxysmal atrial tachycardia with a 2:1 AV response due to digoxin intoxication. (See",
"    <a class=\"local\" href=\"#H13658391\">",
"     'Ectopic atrial tachycardia with block'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13658822\">",
"    <span class=\"h2\">",
"     AV nodal block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    decrease the conduction velocity through the AV node and increase the refractoriness of the AV node; this affects the conduction of the normal as well as a premature impulse. These effects are mediated primarily by an increase in vagal tone and, to a lesser degree, a reduction in sympathetic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/4,17,18,23,29-32\">",
"     4,17,18,23,29-32",
"    </a>",
"    ]. As a result of this dependence on autonomic balance, digoxin is of little value in controlling the ventricular response in patients who have undergone cardiac transplantation due to the denervated nature of the transplanted heart [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AV conduction may be blocked partially or completely by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    excess.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First degree block &ndash; Some degree of PR lengthening may be expected with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      therapy (",
"      <a class=\"graphic graphic_waveform graphicRef67882 \" href=\"UTD.htm?11/45/11989\">",
"       waveform 4",
"      </a>",
"      ). More marked widening of the PR interval to above 0.20 sec suggests early digoxin toxicity.",
"     </li>",
"     <li>",
"      Second degree block &ndash; With higher levels of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , first degree AV block may progress to second degree block of the Mobitz type I (Wenckebach) variety (",
"      <a class=\"graphic graphic_waveform graphicRef73051 \" href=\"UTD.htm?42/35/43573\">",
"       waveform 5",
"      </a>",
"      ). In contrast, Mobitz type II second degree AV block is rarely, if ever, induced by digoxin alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link\">",
"       \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Third degree heart block &ndash; Third-degree (complete) heart block and other types of AV dissociation may also occur with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity (",
"      <a class=\"graphic graphic_waveform graphicRef72863 \" href=\"UTD.htm?20/42/21160\">",
"       waveform 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=see_link\">",
"       \"Third degree (complete) atrioventricular block\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AV block with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is more likely to occur in the presence of atrial fibrillation, an ectopic atrial rhythm, or atrial flutter than during normal sinus rhythm. The reason is that more atrial impulses are present to reach the AV node during these atrial tachyarrhythmias than during slower rates. In atrial fibrillation, a high degree of AV block may occur, resulting in the ventricles being controlled intermittently by a lower junctional or ventricular pacemaker.",
"   </p>",
"   <p>",
"    The ECG findings vary with atrial fibrillation, due to a number of factors, including the possible presence of exit block below the pacemaker. The following additional arrhythmias can be seen with increasing degrees of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity in the presence of atrial fibrillation (",
"    <a class=\"graphic graphic_waveform graphicRef64396 graphicRef76154 graphicRef55119 graphicRef66940 \" href=\"UTD.htm?42/7/43130\">",
"     waveform 3A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/28,33\">",
"     28,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high but not complete degree of AV block in atrial fibrillation will initially lead to single junctional, subjunctional, or ventricular escape beats with a cycle length characteristic of that of the underlying pacemaker. These escape beats recur episodically during a rhythm strip; they can be diagnosed by the demonstration that the recurring longest R-R intervals have a constant cycle length.",
"     </li>",
"     <li>",
"      A higher degree of AV or third degree block results in so few atrial impulses being conducted that a lower pacemaker takes over, leading to an escape junctional, subjunctional, or ventricular rhythm with a slow regular R-R interval for two or more cycles.",
"     </li>",
"     <li>",
"      The presence of an accelerated lower pacemaker (due, eg, to triggered activity causing an accelerated junctional rhythm) with regularization of the R-R intervals, in contrast to the irregularly irregular intervals in atrial fibrillation, strongly suggests",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity. Simply palpating the peripheral pulse in this setting may lead to the erroneous assumption that the patient has converted to sinus rhythm; however, the ECG will continue to show fibrillatory waves [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      More rarely, the lower pacemaker may be regular but there is a Wenckebach type of exit block, resulting in decreasing R-R intervals with group beating characteristic of the Wenckebach phenomenon. Casual evaluation of such a patient who might have severe",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity may lead to the mistaken conclusion that the irregular rhythm is due to persistent atrial fibrillation and the digoxin may be continued or the dose increased. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link\">",
"       \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Even less commonly, impulses from the lower pacemaker travel alternately down the right and left bundle branches, resulting in a bidirectional ventricular tachycardia (",
"      <a class=\"graphic graphic_waveform graphicRef71796 \" href=\"UTD.htm?28/24/29063\">",
"       waveform 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24718477\">",
"       'Bidirectional ventricular tachycardia'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24718286\">",
"    <span class=\"h2\">",
"     Junctional rhythm, tachycardia, and bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV junctional rhythms are sometimes a sign of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity. Digoxin toxicity can result in varying degrees of AV block that may allow the appearance of junctional escape beats and escape junctional (or atrioventricular nodal) rhythms. The junctional rate may be normal (40 to 60",
"    <span class=\"nowrap\">",
"     beats/min),",
"    </span>",
"    accelerated (60 to 120",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    due to direct effects or adrenergic influences), or depressed (less than 40",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    due to enhanced vagal tone, dysfunctional pacemakers in organic heart disease, or to hyperkalemia caused by the digoxin toxicity) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/4,17,18,34\">",
"     4,17,18,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The QRS complex is usually narrow with junctional rhythms, since the pacemaker is typically above the bifurcation of the bundle branches. However, the QRS may be wide if there is a conduction disturbance distal to the pacemaker, a dominant subjunctional pacemaker, or a dominant ventricular pacemaker.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24718293\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of ventricular arrhythmias may result from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity, including ventricular premature beats, ventricular tachycardia, and ventricular fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24718559\">",
"    <span class=\"h3\">",
"     Ventricular premature beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs), often the first sign of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity, are also the most common arrhythmia due to digoxin toxicity. While isolated VPBs may be seen, the VPBs often appear in a bigeminal pattern (",
"    <a class=\"graphic graphic_waveform graphicRef72547 \" href=\"UTD.htm?16/4/16456\">",
"     waveform 8",
"    </a>",
"    ). Although ventricular bigeminy can result from organic heart disease, it should raise the suspicion of digoxin intoxication in relevant contexts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24718566\">",
"    <span class=\"h3\">",
"     Ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to reentry or possibly to triggered membrane activity (delayed afterdepolarizations), ventricular tachycardia (VT) can be induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    excess [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/27\">",
"     27",
"    </a>",
"    ]. With triggered membrane activity, VT may be resistant to interruption by ventricular pacing since the faster rate of pacing may in itself increase the transient inward current and worsen the arrhythmia. The axis and width of the QRS complex on the ECG are determined by the site of origin of the VT, which may be in the specialized fascicles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24718573\">",
"    <span class=\"h3\">",
"     Ventricular fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular fibrillation (VF) can occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity, but is usually a late rhythm. VF can, however, be induced by the use of electric cardioversion in patients with an atrial tachyarrhythmia associated with excess digoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24718477\">",
"    <span class=\"h3\">",
"     Bidirectional ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unusual arrhythmia is the so-called \"bidirectional\" ventricular tachycardia in which the rhythm is regular but every other beat has a different axis as it travels alternately down different conduction pathways (",
"    <a class=\"graphic graphic_waveform graphicRef71796 \" href=\"UTD.htm?28/24/29063\">",
"     waveform 7",
"    </a>",
"    ). In most cases, the rhythm has a right bundle branch block morphology with an alternating left and right axis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/36\">",
"     36",
"    </a>",
"    ]. However, alternating right and left bundle branch patterns may be seen. Bidirectional ventricular tachycardia may be confused with ventricular bigeminy. In true bigeminy, the ventricular beat in the bigeminal pattern is premature. In comparison, the R-R interval is regular with a bidirectional tachycardia, since all of the beats arise from a single focus.",
"   </p>",
"   <p>",
"    Bidirectional ventricular tachycardia is not specific for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    intoxication. It is a frequent finding in familial catecholaminergic polymorphic VT, a much less common disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28072/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link&amp;anchor=H3#H3\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\", section on 'Catecholaminergic polymorphic VT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24718580\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrhythmias resulting from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity are an important and life-threatening clinical problem seen in up to five percent of patients receiving digoxin (or digitoxin). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity appears to be lower than had been seen historically, as a result of several changes in clinical practice including appropriate dose reductions in patients with renal dysfunction, better methods for measuring plasma digoxin levels, and the availability of other medications for the treatment of chronic heart failure and tachyarrhythmias leading to a reduced reliance on digoxin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence of digoxin toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maintaining trough",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      levels at the lower range (eg, between 0.5 and 0.8",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      is recommended to help minimize toxicity.",
"     </li>",
"     <li>",
"      Life-threatening",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      -induced arrhythmias occur at progressively substantially increased frequency as the plasma digoxin concentration rises above 2.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      However, signs of toxicity may occur at much lower plasma levels, especially in the presence of comorbid conditions (eg, hypokalemia, hypomagnesemia, hypercalcemia, myocardial ischemia). Hypokalemia is a particularly important risk factor that can promote digoxin-induced arrhythmias even if the digoxin concentration is thought to be within the \"therapeutic\" range. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence of digoxin toxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Plasma digoxin levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Almost any arrhythmia occurring at almost any intracardiac location can be seen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity, depending in part upon the age of the patient and the state of the myocardium. Accentuation of vagal effects and resulting bradyarrhythmias is more commonly seen in younger, healthier individuals. Conversely, patients with severe cardiac disease and concurrent digoxin toxicity are more susceptible to ventricular ectopy and tachyarrhythmias. (See",
"      <a class=\"local\" href=\"#H13658052\">",
"       'Digoxin-induced arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic concentrations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      have little effect on atrial tissue, but toxic levels may result in an ectopic atrial tachycardia, often with 2:1 AV block. Also referred to as paroxysmal atrial tachycardia, this arrhythmia is strongly suggestive of digoxin toxicity in patients on the drug. However, the arrhythmia is not typically paroxysmal when induced by digoxin; rather, it is a persistent arrhythmia until specific therapy is instituted or digoxin levels fall below the toxic range. (See",
"      <a class=\"local\" href=\"#H13658391\">",
"       'Ectopic atrial tachycardia with block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AV junctional rhythms are frequently a sign of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity. Digoxin toxicity can result in varying degrees of AV block that may allow the appearance of junctional escape beats and escape junctional (or atrioventricular nodal) rhythms. The junctional rate may be normal (40 to 60",
"      <span class=\"nowrap\">",
"       beats/min),",
"      </span>",
"      accelerated (60 to 120",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      due to direct effects or adrenergic influences), or depressed (less than 40",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      due to enhanced vagal tone, dysfunctional pacemakers in organic heart disease, or to hyperkalemia caused by the digoxin toxicity). (See",
"      <a class=\"local\" href=\"#H24718286\">",
"       'Junctional rhythm, tachycardia, and bradycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular premature beats (VPBs), often the first sign of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity, are also the most common arrhythmia due to digoxin toxicity. While isolated VPBs may be seen, the VPBs often appear in a bigeminal pattern (",
"      <a class=\"graphic graphic_waveform graphicRef72547 \" href=\"UTD.htm?16/4/16456\">",
"       waveform 8",
"      </a>",
"      ). Although ventricular bigeminy can result from organic heart disease, it should raise the suspicion of digoxin intoxication. (See",
"      <a class=\"local\" href=\"#H24718559\">",
"       'Ventricular premature beats'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An unusual arrhythmia is the so-called \"bidirectional\" ventricular tachycardia in which the rhythm is regular but every other beat has a different axis as it travels alternately down different conduction pathways (",
"      <a class=\"graphic graphic_waveform graphicRef71796 \" href=\"UTD.htm?28/24/29063\">",
"       waveform 7",
"      </a>",
"      ). Bidirectional ventricular tachycardia may be confused with ventricular bigeminy. In true bigeminy, the ventricular beat in the bigeminal pattern is premature. In comparison, the R-R interval is regular with a bidirectional tachycardia, since all of the beats arise from a single focus. Bidirectional ventricular tachycardia is not specific for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      intoxication; it is also a frequent finding in familial catecholaminergic polymorphic VT. (See",
"      <a class=\"local\" href=\"#H24718477\">",
"       'Bidirectional ventricular tachycardia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/1\">",
"      Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation 2004; 109:2959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/2\">",
"      Hauptman PJ, Kelly RA. Digitalis. Circulation 1999; 99:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/3\">",
"      Hussain Z, Swindle J, Hauptman PJ. Digoxin use and digoxin toxicity in the post-DIG trial era. J Card Fail 2006; 12:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/4\">",
"      Mahdyoon H, Battilana G, Rosman H, et al. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988. Am Heart J 1990; 120:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/5\">",
"      Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992; 69:108G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/6\">",
"      Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005; 46:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/7\">",
"      Williamson KM, Thrasher KA, Fulton KB, et al. Digoxin toxicity: an evaluation in current clinical practice. Arch Intern Med 1998; 158:2444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/8\">",
"      Ahmed A, Pitt B, Rahimtoola SH, et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol 2008; 123:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/9\">",
"      Goldberger ZD, Goldberger AL. Therapeutic ranges of serum digoxin concentrations in patients with heart failure. Am J Cardiol 2012; 109:1818.",
"     </a>",
"    </li>",
"    <li>",
"     Eisner DA, Smith TW. The Na-K pump and its effectors in cardiac muscle. In: The Heart and Cardiovascular System, Fozzard HA, Haber E, Katz AM, Morgan HE (Eds), Raven Press, New York 1991. p.863.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/11\">",
"      Santana LF, G&oacute;mez AM, Lederer WJ. Ca2+ flux through promiscuous cardiac Na+ channels: slip-mode conductance. Science 1998; 279:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/12\">",
"      Sagawa T, Sagawa K, Kelly JE, et al. Activation of cardiac ryanodine receptors by cardiac glycosides. Am J Physiol Heart Circ Physiol 2002; 282:H1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/13\">",
"      Watanabe AM. Digitalis and the autonomic nervous system. J Am Coll Cardiol 1985; 5:35A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/14\">",
"      Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn Circ J 1999; 63:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/15\">",
"      Toda N, West TC. The influence of ouabain on cholinergic responses in the sinoatrial node. J Pharmacol Exp Ther 1966; 153:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/16\">",
"      Goodman DJ, Rossen RM, Ingham R, et al. Sinus node function in the denervated human heart. Effect of digitalis. Br Heart J 1975; 37:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/17\">",
"      Smith TW, Antman EM, Friedman PL, et al. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis 1984; 26:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/18\">",
"      Smith TW, Antman EM, Friedman PL, et al. Digitalis glycosides: mechanisms and manifestations of toxicity. Part II. Prog Cardiovasc Dis 1984; 26:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/19\">",
"      Reiffel JA, Bigger JT Jr, Cramer M. Effects of digoxin on sinus nodal function before and after vagal blockade in patients with sinus nodal dysfunction: a clue to the mechanisms of the action of digitalis on the sinus node. Am J Cardiol 1979; 43:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/20\">",
"      VASSALLE M, GREENSPAN K, HOFFMAN BF. AN ANALYSIS OF ARRHYTHMIAS INDUCED BY OUABAIN IN INTACT DOGS. Circ Res 1963; 13:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/21\">",
"      JAMES TN, NADEAU RA. The chronotropic effect of digitalis studied by direct perfusion of the sinus node. J Pharmacol Exp Ther 1963; 139:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/22\">",
"      Scherlag BJ, Abelleira JL, Narula OS, Samet P. The differential effects of ouabain on sinus, A-V nodal, His bundle, and idioventricular rhythms. Am Heart J 1971; 81:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/23\">",
"      MENDEZ C, ACEVES J, MENDEZ R. Inhibition of adrenergic cardiac acceleration by cardiac glycosides. J Pharmacol Exp Ther 1961; 131:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/24\">",
"      Steinbeck G, Bonke FI, Allessie MA, Lammers WJ. The effect of ouabain on the isolated sinus node preparation of the rabbit studied with microelectrodes. Circ Res 1980; 46:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/25\">",
"      Takayanagi K, Jalife J. Effects of digitalis intoxication on pacemaker rhythm and synchronization in rabbit sinus node. Am J Physiol 1986; 250:H567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/26\">",
"      Geer MR, Wagner GS, Waxman M, Wallace AG. Chronotropic effect of acetylstrophanthidin infusion into the canine sinus nodal artery. Am J Cardiol 1977; 39:684.",
"     </a>",
"    </li>",
"    <li>",
"     Gorgels APM, Vos MA, Smeets JLRM, et al. Delayed afterdepolarizations and atrial and ventricular arrhythmias. In: Cardiac Electrophysiology: A Textbook, Rosen MR, Janse MJ, Wit AL (Eds), Futura Publishing, Mount Kisco 1990. p.341.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/28\">",
"      Kastor JA, Yurchak PM. Recognition of digitalis intoxication in the presence of atrial fibrillation. Ann Intern Med 1967; 67:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/29\">",
"      Carleton RA, Miller PH, Graettinger JS. Effects of ouabain, atropine, and ouabain and atropine on A-V nodal conduction in man. Circ Res 1967; 20:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/30\">",
"      Toda N, West TC. The action of ouabain on the function of the atrioventricular node in rabbits. J Pharmacol Exp Ther 1969; 169:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/31\">",
"      Goodman DJ, Rossen RM, Cannom DS, et al. Effect of digoxin on atioventricular conduction. Studies in patients with and without cardiac autonomic innervation. Circulation 1975; 51:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/32\">",
"      Ricci DR, Orlick AE, Reitz BA, et al. Depressant effect of digoxin on atrioventricular conduction in man. Circulation 1978; 57:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/33\">",
"      Childers R. Classification of cardiac dysrhythmias. Med Clin North Am 1976; 60:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/34\">",
"      Fisch C, Knoebel SB. Digitalis cardiotoxicity. J Am Coll Cardiol 1985; 5:91A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/35\">",
"      Kleiger R, Lown B. Cardioversion and digitalis. II. Clinical studies. Circulation 1966; 33:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/36\">",
"      Morris SN, Zipes DP. His bundle electrocardiography during bidirectional tachycardia. Circulation 1973; 48:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28072/abstract/37\">",
"      Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106:69.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 944 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-A7765D755B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28072=[""].join("\n");
var outline_f27_26_28072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24718580\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE OF DIGOXIN TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Plasma digoxin levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISMS OF CARDIAC TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13658052\">",
"      DIGOXIN-INDUCED ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13658144\">",
"      Sinus bradycardia, tachycardia, block, and arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13658391\">",
"      Ectopic atrial tachycardia with block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13658508\">",
"      Atrial fibrillation and flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13658822\">",
"      AV nodal block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24718286\">",
"      Junctional rhythm, tachycardia, and bradycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24718293\">",
"      Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24718559\">",
"      - Ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24718566\">",
"      - Ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24718573\">",
"      - Ventricular fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24718477\">",
"      - Bidirectional ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24718580\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/944\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/944|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?16/0/16389\" title=\"waveform 1A\">",
"      ECG type I sinoatrial block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?12/56/13189\" title=\"waveform 1B\">",
"      ECG type II sinoatrial block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/17/42262\" title=\"waveform 2\">",
"      ECG atrial tachycardia with block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?37/40/38533\" title=\"waveform 3A\">",
"      ECG digoxin toxicity in AF 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/42/29349\" title=\"waveform 3B\">",
"      ECG digoxin toxicity in AF 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?9/31/9719\" title=\"waveform 3C\">",
"      ECG digoxin toxicity in AF 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?40/25/41365\" title=\"waveform 3D\">",
"      ECG digoxin toxicity in AF 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/45/11989\" title=\"waveform 4\">",
"      ECG first degree AV block I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/35/43573\" title=\"waveform 5\">",
"      ECG Mobitz type I AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/42/21160\" title=\"waveform 6\">",
"      ECG third degree or complete AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/24/29063\" title=\"waveform 7\">",
"      ECG bidirectional VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?16/4/16456\" title=\"waveform 8\">",
"      ECG ventricular bigeminy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=related_link\">",
"      Control of ventricular rate in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38756?source=related_link\">",
"      Sinoatrial nodal pause, arrest, and exit block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_26_28073="Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas";
var content_f27_26_28073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28073/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28073/contributors\">",
"     Christopher P Crum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28073/contributors\">",
"     Jonathan Bijron, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28073/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28073/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28073/contributors\">",
"     Rochelle L Garcia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28073/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28073/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/26/28073/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H636620549\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term epithelial ovarian carcinoma has been used to refer to a large group of malignant neoplasms that typically present as ovarian tumors with involvement of the fallopian tube and peritoneum. Accumulating evidence suggests that these epithelial neoplasms can be divided into two groups in terms of probable site of origin, either ovarian or tubal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first group of carcinomas, which have a plausible origin in the ovary, include those with the following histologies: endometrioid, mucinous, clear cell, borderline, and low grade serous. Some of these appear to arise from endometriosis, a benign condition that may involve the ovaries. This is the case for endometrioid and clear cell carcinomas.",
"   </p>",
"   <p>",
"    M&uuml;llerian inclusions in the ovarian cortex are another potential source of primary ovarian carcinomas. These have been implicated in the development of mucinous and lower grade serous neoplasms. The evidence for this is morphologic evidence of a gradual spectrum of changes seen in the ovary, potentially proceeding from cortical inclusions to cystadenofibromas to borderline and low grade serous carcinomas.",
"   </p>",
"   <p>",
"    The fallopian tubes, uterus, cervix, and upper vagina derive from M&uuml;llerian (paramesonephric) tissue, while the ovary develops from the primordial germ cells and surrounding surface epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/2\">",
"     2",
"    </a>",
"    ]. Primary M&uuml;llerian neoplasms of the ovary likely originate from cells acquired during the reproductive years, possibilities including transport of epithelial cells from the fallopian tubes or endometrium (lining of the uterus). An older theory is M&uuml;llerian metaplasia of ovarian surface epithelium. &nbsp;",
"   </p>",
"   <p>",
"    The second group consists of extrauterine pelvic serous carcinomas, particularly those that are high grade and are associated with a poor prognosis. These have traditionally been thought to be primary ovarian carcinomas, with a few designated as fallopian tube carcinoma (if the bulk of disease was in a fallopian tube) or peritoneal carcinoma (if little or no ovarian or fallopian tube disease was present). The consistent features of these carcinomas have been rapid progression, extra-ovarian disease at the time of diagnosis, and the absence of a known precursor lesion. Current evidence suggests that many of these neoplasms may originate in the fallopian tube. Based upon this theoretical framework, we will use the term \"extrauterine pelvic serous carcinoma\" to refer to these carcinomas, implying a possible origin in the ovary, tube, or M&uuml;llerian epithelium elsewhere in the peritoneal cavity.",
"    <br/>",
"   </p>",
"   <p>",
"    The currently evolving concept of the pathogenesis of extrauterine pelvic serous carcinoma is reviewed here. An overview of the histopathology of ovarian carcinoma and the diagnosis of ovarian, fallopian tube, and peritoneal cancer are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8781633\">",
"    <span class=\"h1\">",
"     POTENTIAL PRECURSOR LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several precursor lesions have been proposed for epithelial ovarian carcinoma, and different types of disease may arise from different precursors. End-stage disease that is similar in appearance may have arisen from different tissues of origin.",
"   </p>",
"   <p>",
"    In this discussion the term \"precursor\" denotes a spectrum of changes preceding invasive or metastatic carcinoma that range from innocuous appearing epithelial changes to those that appear cytologically malignant (highly atypical) but have yet to invade or metastasize. Some precursors are \"latent\" and, while providing clues to the pathogenesis of cancer, are of no clinical significance. These include morphologically normal appearing epithelium in the fallopian tube with clonal mutations of the gene encoding p53 (",
"    <em>",
"     TP53",
"    </em>",
"    ), referred to as p53 signatures, or foci of benign endometriosis with",
"    <em>",
"     ARID1A",
"    </em>",
"    mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/3\">",
"     3",
"    </a>",
"    ]. The focus of the discussion below will be on biologic changes that are morphologically conspicuous and have implications for management.",
"   </p>",
"   <p>",
"    There appear to be different precursor lesions for low grade and high grade extrauterine pelvic serous carcinomas. Low grade neoplasms (including borderline neoplasms and low grade serous carcinoma) may develop gradually due to multiple genetic aberrations in dividing cells that would typically give rise to M&uuml;llerian epithelium, such as ovarian cortical inclusion cysts. The biology of these changes is one encouraging slow growth, preservation of epithelial differentiation, and a more gradual progression to malignant neoplasm, if it occurs. In contrast, the process of neoplastic transformation giving rise to high grade carcinomas includes more dramatic biologic changes that promote a more sudden transition from",
"    <span class=\"nowrap\">",
"     normal/non-neoplastic",
"    </span>",
"    to malignant neoplasm and loss of differentiation. The prototype for this process is the development of serous tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/carcinoma",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620564\">",
"    <span class=\"h2\">",
"     Serous tubal intraepithelial neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential precursor lesion for pelvic high grade serous carcinomas is serous tubal intraepithelial neoplasia (STIN). STIN is an expansile lesion in the fallopian tube with evidence of",
"    <em>",
"     TP53",
"    </em>",
"    mutations and morphologic atypia. Some experts have questioned whether lesions that have low grade morphology are neoplasms.",
"   </p>",
"   <p>",
"    The discovery of STIN has implications for the understanding of the pathogenesis of and the clinical approach to extrauterine pelvic serous carcinoma:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It establishes the fallopian tube as a potential site of origin for many extrauterine pelvic serous carcinomas",
"     </li>",
"     <li>",
"      It underscores the importance of complete examination of the tubes, especially the distal one third in cases with or at risk for serous cancer",
"     </li>",
"     <li>",
"      It expands the debate over the significance of tubal intraepithelial neoplasia in the setting of widespread carcinoma",
"     </li>",
"     <li>",
"      Most importantly, it has ignited a debate over the histologic threshold and rationale for a diagnosis of \"intraepithelial carcinoma\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Histologically, there is a spectrum of tubal",
"    <span class=\"nowrap\">",
"     atypias/lesions",
"    </span>",
"    that might be classified as STIN and it is difficult to determine which of these lesions should be approached as potentially life threatening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neoplastic. Many lesions, while expansile, do not exhibit sufficient epithelial atypia to warrant concern. Such abnormalities might simply be diagnosed as tubal atypia with an understanding that they are not malignant, may not be neoplastic, and impose no risk to the patient once removed. Terms that have been applied to these lesions include",
"    <strong>",
"     serous tubal intraepithelial lesions (STIL)",
"    </strong>",
"    or premalignant atypias. The possibility that such atypias could shed cells to the peritoneum that will later become malignant exists, but is unproven. Thus, based on what is known at this time, these lesions require no further action. Histologic features of STILs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A process occupying one or more tubal plicae",
"     </li>",
"     <li>",
"      A pseudostratified cohesive epithelium with preserved cell orientation",
"     </li>",
"     <li>",
"      Low proliferative index",
"     </li>",
"     <li>",
"      Preservation of ciliated differentiation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other lesions exhibit histologic features that are virtually identical to the morphologic changes associated with intraepithelial carcinoma of the endometrium. We refer to these as",
"    <strong>",
"     serous tubal intraepithelial carcinoma (STIC)",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef86927 \" href=\"UTD.htm?0/0/15\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In contrast, some experts advise that given that the risk of high grade serous tubal intraepithelial neoplasm in the absence of other disease is not known or low, the term carcinoma should not be used to describe these lesions.",
"   </p>",
"   <p>",
"    These lesions exhibit the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Variably stratified fallopian tube epithelium with nuclear pleomorphism",
"     </li>",
"     <li>",
"      An increased",
"      <span class=\"nowrap\">",
"       nuclear/cytoplasmic",
"      </span>",
"      ratio",
"     </li>",
"     <li>",
"      Prominent nucleoli",
"     </li>",
"     <li>",
"      Variable loss of cell polarity with intraepithelial fractures, loss of cohesion, exfoliation",
"     </li>",
"     <li>",
"      Increased proliferation with an intact basement membrane",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intraepithelial neoplasm in the fallopian tube was described as early as 1950 as a potential precursor of fallopian tube serous carcinoma, but it was not until the 2000s that a broader role in the carcinogenesis of extrauterine pelvic serous carcinoma was suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The increasing interest in the role of STIC was based upon findings in women with",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutations. Risk-reducing bilateral salpingo-oophorectomy (rrBSO) is recommended for these women, and this practice became more common in the 1990s. This resulted in histologic evaluation of the fallopian tubes in women with no apparent ovarian lesion. Further, use of extensive sectioning of the tubes has allowed better diagnosis of these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence supporting the role of tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STIC",
"    </span>",
"    in the pathogenesis of extrauterine pelvic serous carcinoma includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among women with an increased risk of ovarian carcinoma (most with",
"      <em>",
"       BRCA",
"      </em>",
"      mutations) who underwent rrBSO, 4 to 17 percent are found to have a pelvic serous preinvasive or invasive neoplasm, and approximately 80 percent of these neoplasms are in the fallopian tube (",
"      <a class=\"graphic graphic_table graphicRef86928 \" href=\"UTD.htm?17/37/18012\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/12-19\">",
"       12-19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The incidence of tubal intraepithelial",
"      <span class=\"nowrap\">",
"       neoplasia/STIC",
"      </span>",
"      in women other than",
"      <em>",
"       BRCA",
"      </em>",
"      mutation carriers is unknown, including women with Lynch syndrome who are also at an increased risk of extrauterine pelvic serous carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/20\">",
"       20",
"      </a>",
"      ]. One small retrospective study found tubal hyperplasia or dysplasia only in women with",
"      <em>",
"       BRCA1",
"      </em>",
"      mutations who underwent rrBSO and not in women who had a salpingectomy for benign gynecologic disease (rrBSO: 11 of 12; benign surgery: 0 of 13) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/21\">",
"       21",
"      </a>",
"      ]. At our institution, we evaluate all tubal specimens with transverse sectioning at 2 to 3 mm (sectioning and extensively examining the fimbrial end [SEE-FIM]). Since 2005, using this protocol, six incidental STICs have been found in women without an ovarian carcinoma, for a frequency of approximately 1:700 in women over age 50 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/22\">",
"       22",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Most cases of serous tubal intraepithelial neoplasia are found in the distal fallopian tube or fimbriated end of the tube, coinciding with the region in which some data suggest that most early tubal adenocarcinomas are found in asymptomatic women [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tubal intraepithelial",
"      <span class=\"nowrap\">",
"       neoplasia/STIC",
"      </span>",
"      and extrauterine pelvic serous carcinoma in the same patient often show identical",
"      <em>",
"       TP53",
"      </em>",
"      mutations, implying a common origin [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/5,24,25\">",
"       5,24,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STIC",
"    </span>",
"    is the earliest potentially clinically significant serous neoplasm of the upper female reproductive tract (ovary or fallopian tubes) that has been identified. The risk that this neoplasm will develop into an invasive tubal carcinoma or spread to the ovarian surface or pelvic peritoneum has not been determined. However, the rarity with which this entity is found in the absence of invasive carcinoma is noteworthy. It contrasts with the traditional image of cancer precursors (such as in the cervix) that accumulate due to their slow or incomplete transit to carcinoma and are thus much more prevalent than their invasive counterparts.",
"   </p>",
"   <p>",
"    There have been occasional cases of recurrent extrauterine pelvic serous carcinoma reported in women with a prior finding of tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STIC",
"    </span>",
"    on rrBSO. In our experience, only about 5 percent recur; which despite the rarity and malignant appearance of tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STIC,",
"    </span>",
"    suggests there is an interval of unknown duration prior to invasion or spread. &nbsp;",
"   </p>",
"   <p>",
"    On the other hand, tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STICs",
"    </span>",
"    are found in association with 33 to 59 percent of cases of locally advanced or metastatic extrauterine pelvic serous carcinoma, irrespective of genetic risk (",
"    <a class=\"graphic graphic_table graphicRef86931 \" href=\"UTD.htm?41/30/42475\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/5,26-30\">",
"     5,26-30",
"    </a>",
"    ]. The presence of STIC in association with advanced stage disease implies that the STIC was discovered after acquiring properties that promoted spread to distant sites, specifically the ovarian and peritoneal surfaces. An alternative explanation is that STIC is produced by mucosal metastases from carcinomas originating elsewhere. In either case, the genetic link between STIC and adjacent carcinomas has been made by the finding of common",
"    <em>",
"     TP53",
"    </em>",
"    mutations in both sites.",
"   </p>",
"   <p>",
"    Since the data regarding STIC derive mainly from women with",
"    <em>",
"     BRCA",
"    </em>",
"    mutations, some have proposed that this patient population may be more prone to oviductal carcinomas. This is difficult to study, because the populations being sampled vary across institutions. Nevertheless, some experts have proposed that up to 30 percent of extrauterine pelvic serous carcinomas with a tubal origin will prove to be",
"    <em>",
"     BRCA",
"    </em>",
"    positive [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/31\">",
"     31",
"    </a>",
"    ]. Further study of this issue is needed.",
"   </p>",
"   <p>",
"    If tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STIC",
"    </span>",
"    is ultimately found to be associated disproportionately with",
"    <em>",
"     BRCA",
"    </em>",
"    mutations, evaluation for this finding in tubal specimens may play a role in detection of mutations carriers. If a tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STIC",
"    </span>",
"    is found following salpingectomy in a woman who has no known genetic risk, counseling regarding genetic testing of the patient could be provided [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. In our practice, we routinely examine the distal fallopian tube of all patients who undergo salpingectomy, whether for rrBSO or other indications. This is analogous to examining the cervix in all hysterectomies to exclude an occult cervical cancer. Given that the distal tube is another site vulnerable to developing neoplasm, we consider it a reasonable approach and it is supported by current recommendations for the pathologic exam of the fallopian tubes and ovaries in surgical pathology specimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620571\">",
"    <span class=\"h2\">",
"     Ovarian cortical inclusion cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prominent hypothesis of the pathogenesis of epithelial ovarian carcinoma is &ldquo;incessant ovulation&rdquo;, which describes a process of repeated ovulation that induces oxidative damage to the ovarian cortex and eventually leads to malignant transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/32\">",
"     32",
"    </a>",
"    ]. Ovulation itself combined with ovarian surface adhesions is implicated in the incorporation of M&uuml;llerian epithelium into the ovarian cortex. &nbsp;",
"   </p>",
"   <p>",
"    Inclusion cysts of the ovarian cortex, derived from these mechanisms, have been reported to express p53 when they occur in conjunction with serous ovarian carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/33\">",
"     33",
"    </a>",
"    ]. However, a direct molecular link between cortical inclusion cysts and serous carcinoma has not been established. Cortical inclusion cysts are more commonly observed in continuity with low grade serous tumors, including serous cystadenomas or cystadenofibromas. These entities merge gradually with borderline (atypical proliferative) serous tumors. Occasionally, high grade serous tumors are seen in continuity with these neoplasms, but this is considered an uncommon pathway to extrauterine pelvic serous carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620578\">",
"    <span class=\"h2\">",
"     Endometriosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriotic foci may be the origin of a small subset of serous ovarian carcinomas. Although this occurs most commonly with endometrioid carcinoma, occasional early serous carcinomas or mixed serous and endometrioid carcinomas arising within areas of endometriosis have been reported. Recent studies have linked mutation in",
"    <em>",
"     ARID1A",
"    </em>",
"    with endometrioid and clear cell carcinomas arising in endometriosis, although this gene does not appear linked to serous neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/3,34\">",
"     3,34",
"    </a>",
"    ]. Larger studies are warranted to determine the true significance of endometriosis in serous carcinogenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H8971849#H8971849\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Link to cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H585879\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF PELVIC SEROUS NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;High grade and low grade pelvic serous carcinogenesis appear to occur through two independent pathways. This is true in the great majority of cases, although some evidence indicates that in rare instances high grade serous carcinoma can develop from low grade carcinoma. In these cases, the high grade lesion typically lack the characteristic",
"    <em>",
"     TP53",
"    </em>",
"    mutation and instead display a similar",
"    <em>",
"     KRAS",
"    </em>",
"    mutation to the one found in the low grade carcinoma from which it originated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620594\">",
"    <span class=\"h2\">",
"     High grade pelvic serous carcinoma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620601\">",
"    <span class=\"h3\">",
"     Origins",
"    </span>",
"    &nbsp;&mdash;&nbsp;High grade serous ovarian, fallopian tubal, and peritoneal carcinomas consist of a cell population that most closely resembles the epithelium of the fallopian tube. It is therefore believed to originate from M&uuml;llerian cells. Although the presence of the main cell types lining the fallopian tube, secretory and ciliated cells, can be readily observed in well-differentiated carcinomas, high grade carcinomas tend to contain a predominantly secretory or non-ciliated population. This is consistent with other carcinoma types in which less differentiation means regression to a less mature cell type, in this case secretory cells. In most cases, high grade carcinomas are thought to represent rapid progression from foci of serous tubal intraepithelial neoplasia (STIN) or inclusion cysts, a process primarily driven by mutations of the",
"    <em>",
"     TP53",
"    </em>",
"    gene [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, most high grade serous carcinomas associated with an ovarian mass were thought to have originated in the ovary. Based upon the available evidence, however, it appears that primary fallopian tubal carcinoma accounts for 35 to 64 percent of extrauterine pelvic serous carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/5,12,26-28\">",
"     5,12,26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assigning a tissue of origin to an advanced stage high grade serous carcinoma is often a challenge. However, as a general rule of thumb, the following distinction may be followed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the majority of the tumor is in the ovary and there are no precursors or early invasive lesions at other sites, ovarian origin is most likely.",
"     </li>",
"     <li>",
"      If there is a bulky fallopian tubal tumor, a serous tubal intraepithelial neoplasm (STIC) is present, and there is minimal involvement of the ovary, primary tubal origin is assumed. Primary tubal carcinomas can be further subclassified as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Extrauterine pelvic serous carcinoma with adhesed fimbria (classic presentation)",
"     </li>",
"     <li>",
"      Advanced pelvic carcinoma with tubal intraepithelial",
"      <span class=\"nowrap\">",
"       neoplasia/STIC",
"      </span>",
"      as the only tubal manifestation",
"     </li>",
"     <li>",
"      Tubal intraepithelial",
"      <span class=\"nowrap\">",
"       neoplasia/STIC",
"      </span>",
"      without the presence of invasive carcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If an intraperitoneal mass is present, and other sites of origin have been excluded by their lack of involvement by neoplasm or the absence of a candidate source (such as a STIC, endometriosis or a preexisting borderline tumor or endometrial primary), the site of origin may be designated as peritoneal carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/37\">",
"       37",
"      </a>",
"      ]. However, this is a diagnosis of exclusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620609\">",
"    <span class=\"h3\">",
"     High grade endometrioid carcinoma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620617\">",
"    <span class=\"h4\">",
"     Histologic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic rigid distinction made between high grade serous and endometrioid carcinomas is controversial. A subgroup of high-grade endometrioid carcinomas have been shown to harbor",
"    <em>",
"     TP53",
"    </em>",
"    mutations, a finding previously mainly associated with serous carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. In addition, this small group of carcinomas often shows strong and diffuse expression of other markers commonly up-regulated in serous carcinoma, such as",
"    <em>",
"     WT1",
"    </em>",
"    and",
"    <em>",
"     p16INK4",
"    </em>",
"    , in marked contrast to the heterogeneous expression pattern seen in low grade endometrioid carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/27,40\">",
"     27,40",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"   </p>",
"   <p>",
"    The clinician can expect in most cases of high grade epithelial carcinoma to receive a diagnosis of either high grade serous carcinoma or mixed serous and endometrioid carcinoma. An alternative is simply &ldquo;high grade M&uuml;llerian carcinoma&rdquo;, which avoids the decision of separating endometrioid, serous, or transitional patterns, and connotes a spectrum of disease that receives uniform treatment.",
"   </p>",
"   <p>",
"    Regarding pathogenesis, it remains to be seen whether subtle differences in histologic type (endometrioid versus serous) for high grade carcinomas reflect differences in origin. One study reported that high grade serous carcinoma is more likely to be associated with tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STIC",
"    </span>",
"    and involve both ovaries equally, whereas high grade endometrioid carcinoma has minimal relationship to tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STIC",
"    </span>",
"    and tends to favor one ovary over the other [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2660850\">",
"    <span class=\"h4\">",
"     Evaluation of rrBSO specimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STIC",
"    </span>",
"    has been found in many of the tubal specimens in women with a BRCA mutation related hereditary ovarian cancer syndrome. The risk of STIC in women with Lynch syndrome is unknown, although a proportion of ovarian cancers in these women are high grade serous carcinomas. More recent larger series of BRCA-positive women undergoing rrBSO with complete examination of the fimbria report finding early carcinomas at a rate of between 1 and 10 percent and 78 percent or more will involve the distal tubal mucosa (",
"    <a class=\"graphic graphic_table graphicRef86928 \" href=\"UTD.htm?17/37/18012\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/12-18\">",
"     12-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the ovarian and tubal specimens following rrBSO require careful examination for neoplasm. We use the SEE-FIM protocol at our institution [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/11\">",
"     11",
"    </a>",
"    ]. If tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STIC",
"    </span>",
"    is found and the pelvic washings are negative, conservative management is the usual choice. It is unclear whether a second procedure is needed for staging.",
"   </p>",
"   <p>",
"    An issue that has challenged pathologists is the distinction of tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STIC",
"    </span>",
"    from a lesser form of atypia that does not confer any risk of recurrence. Many atypias are minor, some of which might contain p53 mutations (p53 signatures). These may have an etiologic connection to cancer but are inconsequential in the removed tube, not unlike a low grade dysplasia of the cervix in a hysterectomy specimen (",
"    <a class=\"graphic graphic_picture graphicRef86932 \" href=\"UTD.htm?17/56/18313\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/24\">",
"     24",
"    </a>",
"    ]. However, some of these will be particularly expansile or border histologically on STIC and may cause some diagnostic uncertainty. These premalignant atypias have been termed tubal intraepithelial lesions in transition (TILTs) or simply TILs by some in the pathology community. The clinician must be aware of such lesions when the pathology report is indecisive. One solution to such difficulties is to have the tissue sections reviewed by multiple reviewers and to immunostain the lesion with markers of proliferation (MIB1) and p53 to confirm the presence of abnormal p53 staining and a high proliferative index. However ultimately, the decision is based on histologic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/11\">",
"     11",
"    </a>",
"    ]. As discussed above, the caregiver must be aware of the fact that approximately 5 percent of tubal intraepithelial",
"    <span class=\"nowrap\">",
"     neoplasia/STICs,",
"    </span>",
"    when found in isolation, will be followed by a recurrence. Importantly, the patient must be counseled that some women with BRCA mutations develop extrauterine pelvic serous carcinoma following a completely normal rrBSO [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link&amp;anchor=H12#H12\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\", section on 'Surveillance for peritoneal cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early diagnosis of (pre)cancerous lesions (in situ neoplasms) is mainly limited by the physical location of the ovaries and fallopian tubes. Nevertheless, the fact that over 80 percent of symptomatic high grade extrauterine pelvic serous carcinomas have already spread beyond the ovary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/42\">",
"     42",
"    </a>",
"    ] demands a more critical and innovative look at extrauterine pelvic serous carcinoma prevention. Alternatives to more traditional approaches (such as periodic physical exam, ultrasound or serologic testing) merit study and the concept of targeted prevention, in which one or more steps of early carcinogenesis are interrupted, is an attractive concept.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2660518\">",
"    <span class=\"h4\">",
"     Assigning primary tumor site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assignment of primary site has little clinical relevance, since high grade serous carcinomas arising in the ovary, tube, or peritoneum have the same clinical behavior and treatment. Traditionally, there have been criteria to distinguish between these carcinomas. However, many cases that were presumed to be ovarian carcinoma may have been incorrectly designated. Careful examination of the oviduct will reveal a STIC in approximately half of \"peritoneal\" serous carcinomas. This will not alter the management, but would be an indication for genetic testing.",
"   </p>",
"   <p>",
"    Peritoneal carcinoma (previously referred to as primary peritoneal serous carcinoma) has long been a diagnosis of exclusion. Serous carcinomas involving the peritoneum and primarily serosal surfaces of the tubes and ovaries have been designated as peritoneal out of a lack of better choice for a primary site. However, other than occasional cases arising from pelvic endometriosis, no precursor lesion has been identified, and recent studies suggest that up to 50 percent might originate in the fallopian tube. This is further support for the all-encompassing term &ldquo;extrauterine pelvic serous carcinoma&rdquo;, which avoids the use of potentially inappropriate assignment of tumor origin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/26,29\">",
"     26,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, careful examination of the fallopian tubes with attention to the fimbria is required for all cases of extrauterine pelvic serous carcinoma. In our practice, we have developed the SEE-FIM protocol for this evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/11\">",
"     11",
"    </a>",
"    ]. If an origin in the tubes, ovaries, and peritoneum cannot be found, we use the term extrauterine pelvic serous carcinoma with no designation of primary site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620624\">",
"    <span class=\"h3\">",
"     Targeted therapy (PARP inhibitors)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poly ADP ribose polymerase (PARP) inhibitors are a relatively novel drug class that inhibit the PARP proteins responsible for repairing single-strand DNA breaks.",
"   </p>",
"   <p>",
"    Interruption of this repair mechanism has been shown to accelerate the accumulation of DNA damage in carcinoma, in particular in carcinoma types carrying mutations in (mismatch) repair genes, such as",
"    <em>",
"     BRCA",
"    </em>",
"    1 and 2. Fong et al 2009 described durable antitumor activity in 8 out of 16",
"    <em>",
"     BRCA",
"    </em>",
"    associated ovarian carcinomas but no effectiveness in sporadic tumors (n=5) and found similar results for",
"    <em>",
"     BRCA",
"    </em>",
"    associated breast and prostate carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/43\">",
"     43",
"    </a>",
"    ]. However, a recent study, in addition to validating the results in",
"    <em>",
"     BRCA",
"    </em>",
"    mutation carriers (in 7 of 17 patients, 41 percent), did show an effect in an albeit smaller percentage of sporadic high grade serous carcinoma (11 of 43 patients, 24 percent), which may have been the result of the larger sample size or due to the specific selection of high grade serous and undifferentiated carcinomas in this study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/44\">",
"     44",
"    </a>",
"    ]. A possible explanation for this finding may be that up to 50 percent of sporadic high grade serous carcinomas have lost",
"    <em>",
"     BRCA",
"    </em>",
"    1 or 2 due to somatic mutations or epigenetic events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/45\">",
"     45",
"    </a>",
"    ], and in these cases, PARP inhibitors may be able to exert their antitumor activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620639\">",
"    <span class=\"h2\">",
"     Low grade serous neoplasms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620647\">",
"    <span class=\"h3\">",
"     Origins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low grade serous ovarian carcinoma and serous borderline ovarian neoplasms appear to originate in the ovaries and to have a common pathogenesis. These neoplasms lack a well defined precursor condition in the fallopian tube and most experts think it is likely that they originate in the ovaries and, in some cases, extraovarian endosalpingiosis.",
"   </p>",
"   <p>",
"    Low grade serous neoplasms, like high grade carcinomas, have the propensity for peritoneal spread. Low grade ovarian serous carcinomas differ from high grade extrauterine pelvic serous carcinomas in various ways, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cellular features more closely resembling benign mucosa, often with preservation of discernible ciliated differentiation",
"     </li>",
"     <li>",
"      Lower proliferative index",
"     </li>",
"     <li>",
"      Lack of",
"      <em>",
"       TP53",
"      </em>",
"      mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      No known precursor in the fallopian tubes",
"     </li>",
"     <li>",
"      Frequent close geographical ties to areas of serous borderline tumors, from which it can be distinguished by the presence of frank stromal invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/35,46,47\">",
"       35,46,47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most low grade serous neoplasms do not have an obvious precursor in the oviduct, but the oviducts from these cases may hold clues to their pathogenesis. Reports of proliferations in the tube, including discrete secretory cell outgrowths (SCOUTs), suggest that the likelihood of functional gene alterations is increased in these patients (",
"    <a class=\"graphic graphic_picture graphicRef86933 \" href=\"UTD.htm?12/8/12426\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Further study is needed to determine whether these changes indicate an early phase of precursor development in the tube that makes its way to the ovary or peritoneum.",
"   </p>",
"   <p>",
"    In terms of pathogenesis, the cell types found in low grade serous carcinoma and borderline neoplasms closely resemble tubal epithelium, similar to high grade serous pelvic carcinoma. However, low grade and borderline tumors display ciliated differentiation, indicating that the cell of origin is capable of ciliogenesis. It not known whether this reflects a unique target cell (ie, one that inherently undergoes ciliated differentiation) or gene perturbations that are different from high grade carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low grade serous ovarian neoplasms are presumed to arise from ectopic M&uuml;llerian epithelium, which can be found in ovarian cortical inclusion cysts. These inclusions have been postulated to arise from the mesothelial surface lining through either transdifferentiation or direct transfer from the distal fallopian tube. (See",
"    <a class=\"local\" href=\"#H636620571\">",
"     'Ovarian cortical inclusion cysts'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The presence of ovarian stroma and a subsequent epithelial-stromal interaction appears to be integral to carcinogenesis. A large percentage of low grade neoplasms acquire either",
"    <em>",
"     KRAS",
"    </em>",
"    or",
"    <em>",
"     BRAF",
"    </em>",
"    mutations during their development, which are not typically present high grade serious carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. BRAF mutations at codon 600 occur in approximately 30 percent of low grade serous carcinomas and 28 percent of serous borderline tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/52\">",
"     52",
"    </a>",
"    ]. However, another study found that",
"    <em>",
"     BRAF",
"    </em>",
"    mutations were relatively rare in advanced stage low grade serous carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/55\">",
"     55",
"    </a>",
"    ]. Thus, KRAS mutations may be more important in the initiation of progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another group of genes that are thought to play a role in the transformation of ectopic M&uuml;llerian epithelium in the ovaries are the homeobox regulatory (",
"    <em>",
"     HOX",
"    </em>",
"    ) genes. During the development of the female genital tract,",
"    <em>",
"     HOX",
"    </em>",
"    genes are differentially expressed throughout the M&uuml;llerian epithelium, but in adults, the different members become site specific, with",
"    <em>",
"     HOXA9",
"    </em>",
"    expression found in the fallopian tubes,",
"    <em>",
"     HOXA10",
"    </em>",
"    in the uterus,",
"    <em>",
"     HOXA11",
"    </em>",
"    in the lower uterine segment, and",
"    <em>",
"     HOXA13",
"    </em>",
"    in the upper vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/56\">",
"     56",
"    </a>",
"    ]. In mice, ectopic expression of",
"    <em>",
"     HOXA9",
"    </em>",
"    in ovarian surface epithelium leads to the development of serous-like epithelial tumors, while",
"    <em>",
"     HOXA10",
"    </em>",
"    and",
"    <em>",
"     HOXA11",
"    </em>",
"    produce endometrioid-like and mucinous-like neoplasms, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/57\">",
"     57",
"    </a>",
"    ]. Ectopic expression of",
"    <em>",
"     HOX",
"    </em>",
"    genes thus may be an important step in neoplastic transformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620655\">",
"    <span class=\"h3\">",
"     Clinical issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620662\">",
"    <span class=\"h4\">",
"     Classification and chemoresponsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinguishing between low and high grade serous carcinomas is important based on the vastly differing modes of disease progression and inherent tumor characteristics (eg, responsiveness to chemotherapy); it is typically done by evaluating mitotic rate (low in low grade and high in high grade) and nuclear grade, but making this distinction can be challenging.",
"   </p>",
"   <p>",
"    For neoplasms that are not readily classified as low or high grade, immunostaining for p53 is helpful. Strongly positive or completely absent p53 staining corresponds to inactivation of",
"    <em>",
"     TP53",
"    </em>",
"    , hence high grade serous carcinoma. The latter (complete loss of staining) is explained by deletion of the portion of p53 that encodes the protein that is recognized by the antibody. This is equivalent to inactivation by point mutation.",
"   </p>",
"   <p>",
"    Multiple studies have reported on the relative chemoresistance of low grade ovarian carcinoma compared to their high grade carcinoma. Response rates for all extrauterine pelvic serous carcinomas (which based on prevalence mainly comprises high grade carcinomas) to platinum-based chemotherapy are approximately 26 percent when given as treatment for primary disease and 27 to 66 percent for recurring, established platinum-sensitive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/58-61\">",
"     58-61",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    In contrast, for solely low grade carcinomas, response rates of 4 percent for primary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/62\">",
"     62",
"    </a>",
"    ] and 4.9 percent for recurrent disease were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/63\">",
"     63",
"    </a>",
"    ]. These differences might theoretically be explained by the slower proliferation rate of low grade carcinoma, thus limiting the accumulation of platinum intercalation induced DNA damage, but there is no direct molecular evidence of this.",
"   </p>",
"   <p>",
"    It should be noted that resistance to chemotherapy does not translate directly to survival rates. Based upon their indolent growth pattern, low grade serous carcinomas have significantly longer progression free survival rates than high grade lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28073/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemoresponsiveness of ovarian, fallopian tubal, and peritoneal carcinomas is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250841395#H250841395\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'In vitro chemosensitivity and resistance assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H636620701\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term epithelial ovarian carcinoma has been used to refer to a large group of malignant neoplasms that typically present as ovarian tumors with involvement of the fallopian tube and peritoneum. Accumulating evidence suggests that these epithelial neoplasms can be divided into two groups in terms of probable site of origin, ovarian or tubal. (See",
"      <a class=\"local\" href=\"#H636620549\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data from women with",
"      <em>",
"       BRCA",
"      </em>",
"      mutations who have undergone risk-reducing salpingo-oophorectomy suggest that many high grade serous carcinomas classified as either ovarian or peritoneal have a precursor lesion in the fallopian tube. (See",
"      <a class=\"local\" href=\"#H636620564\">",
"       'Serous tubal intraepithelial neoplasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serous tubal intraepithelial",
"      <span class=\"nowrap\">",
"       neoplasia/carcinoma",
"      </span>",
"      is the lesion that has been identified as the likely precursor lesion.",
"      <em>",
"       TP53",
"      </em>",
"      mutations, the tubal secretory cell and involvement of the distal fallopian tube, characterize this entity. (See",
"      <a class=\"local\" href=\"#H636620564\">",
"       'Serous tubal intraepithelial neoplasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cortical inclusion cysts and endometriosis give rise to neoplasms that are distinctly ovarian in origin, including mucinous, endometrioid, clear cell, and low grade serous neoplasms. The origin of these neoplasms involves molecular perturbations of genes other than",
"      <em>",
"       TP53",
"      </em>",
"      , including",
"      <em>",
"       KRAS",
"      </em>",
"      ,",
"      <em>",
"       BRAF",
"      </em>",
"      ,",
"      <em>",
"       PTEN",
"      </em>",
"      , and",
"      <em>",
"       ARID1A",
"      </em>",
"      . (See",
"      <a class=\"local\" href=\"#H636620571\">",
"       'Ovarian cortical inclusion cysts'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H636620578\">",
"       'Endometriosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/1\">",
"      Tone AA, Salvador S, Finlayson SJ, et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012; 10:296.",
"     </a>",
"    </li>",
"    <li>",
"     Blaustein's Pathology of the Female Genital Tract, 6th ed, Kurman RJ, Ellenson LH, Ronnett RM.  (Eds), Springer, New York 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/3\">",
"      Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/4\">",
"      Kurman RJ, Visvanathan K, Roden R, et al. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008; 198:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/5\">",
"      Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31:161.",
"     </a>",
"    </li>",
"    <li>",
"     Alvarado-Cabrero I, Cheung A, Caduff R. Tumours of the fallopian tube. In: Tumours of the Breast and Female Genital Organs: WHO Classification of Tumours, Tavassoli FA, Devilee P (Eds), IARC Press, Lyon, France 2003. p.206.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/7\">",
"      Colgan TJ. Challenges in the early diagnosis and staging of Fallopian-tube carcinomas associated with BRCA mutations. Int J Gynecol Pathol 2003; 22:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/8\">",
"      HU CY, TAYMOR ML, HERTIG AT. Primary carcinoma of the fallopian tube. Am J Obstet Gynecol 1950; 59:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/9\">",
"      SEDLIS A. Primary carcinoma of the fallopian tube. Obstet Gynecol Surv 1961; 16:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/10\">",
"      Yoonessi M. Carcinoma of the fallopian tube. Obstet Gynecol Surv 1979; 34:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/11\">",
"      Mehrad M, Ning G, Chen EY, et al. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol 2010; 17:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/12\">",
"      Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001; 25:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/13\">",
"      Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002; 87:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/14\">",
"      Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005; 23:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/15\">",
"      Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006; 100:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/16\">",
"      Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25:3985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/17\">",
"      Carcangiu ML, Peissel B, Pasini B, et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol 2006; 30:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/18\">",
"      Hirst JE, Gard GB, McIllroy K, et al. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer 2009; 19:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/19\">",
"      Reitsma W, de Bock GH, Oosterwijk JC, et al. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 2013; 49:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/20\">",
"      Schmeler KM, Daniels MS, Soliman PT, et al. Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol 2010; 115:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/21\">",
"      Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195:451.",
"     </a>",
"    </li>",
"    <li>",
"     Conner J, Crum C, Feltmate C, Brigham and Women's Hospital, Harvard Medical School, unpublished data.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/23\">",
"      Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/24\">",
"      Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/25\">",
"      Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/26\">",
"      Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008; 26:4160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/27\">",
"      Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol 2009; 33:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/28\">",
"      Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010; 34:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/29\">",
"      Seidman JD, Zhao P, Yemelyanova A. \"Primary peritoneal\" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011; 120:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/30\">",
"      Leonhardt K, Einenkel J, Sohr S, et al. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol 2011; 30:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/31\">",
"      Vicus D, Finch A, Cass I, et al. Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. Gynecol Oncol 2010; 118:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/32\">",
"      Fathalla MF. Incessant ovulation--a factor in ovarian neoplasia? Lancet 1971; 2:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/33\">",
"      Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995; 27:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/34\">",
"      Oral E, Ilvan S, Tustas E, et al. Prevalence of endometriosis in malignant epithelial ovary tumours. Eur J Obstet Gynecol Reprod Biol 2003; 109:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/35\">",
"      Dehari R, Kurman RJ, Logani S, Shih IeM. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 2007; 31:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/36\">",
"      Salani R, Kurman RJ, Giuntoli R 2nd, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 2008; 18:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/37\">",
"      Carlson J, Roh MH, Chang MC, Crum CP. Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube. Diagn Histopathol (Oxf) 2008; 14:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/38\">",
"      Geyer JT, L&oacute;pez-Garc&iacute;a MA, S&aacute;nchez-Estevez C, et al. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol 2009; 33:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/39\">",
"      Madore J, Ren F, Filali-Mouhim A, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol 2010; 220:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/40\">",
"      K&ouml;bel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008; 5:e232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/41\">",
"      Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006; 296:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/42\">",
"      Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/43\">",
"      Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/44\">",
"      Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/45\">",
"      Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/46\">",
"      Singer G, St&ouml;hr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/47\">",
"      O'Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005; 29:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/48\">",
"      Laury AR, Ning G, Quick CM, et al. Fallopian tube correlates of ovarian serous borderline tumors. Am J Surg Pathol 2011; 35:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/49\">",
"      Kurman RJ, Vang R, Junge J, et al. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 2011; 35:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/50\">",
"      Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/51\">",
"      Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002; 160:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/52\">",
"      Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/53\">",
"      Sieben NL, Macropoulos P, Roemen GM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004; 202:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/54\">",
"      Mayr D, Hirschmann A, L&ouml;hrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006; 103:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/55\">",
"      Wong KK, Tsang YT, Deavers MT, et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 2010; 177:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/56\">",
"      Taylor HS, Vanden Heuvel GB, Igarashi P. A conserved Hox axis in the mouse and human female reproductive system: late establishment and persistent adult expression of the Hoxa cluster genes. Biol Reprod 1997; 57:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/57\">",
"      Cheng W, Liu J, Yoshida H, et al. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005; 11:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/58\">",
"      International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/59\">",
"      Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/60\">",
"      Dizon DS, Dupont J, Anderson S, et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2003; 91:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/61\">",
"      Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/62\">",
"      Schmeler KM, Sun CC, Bodurka DC, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008; 108:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/63\">",
"      Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009; 114:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28073/abstract/64\">",
"      Bodurka DC, Deavers MT, Tian C, et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 2012; 118:3087.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16558 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28073=[""].join("\n");
var outline_f27_26_28073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H636620701\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H636620549\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8781633\">",
"      POTENTIAL PRECURSOR LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636620564\">",
"      Serous tubal intraepithelial neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636620571\">",
"      Ovarian cortical inclusion cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636620578\">",
"      Endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H585879\">",
"      CHARACTERISTICS OF PELVIC SEROUS NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636620594\">",
"      High grade pelvic serous carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H636620601\">",
"      - Origins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H636620609\">",
"      - High grade endometrioid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H636620617\">",
"      Histologic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2660850\">",
"      Evaluation of rrBSO specimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2660518\">",
"      Assigning primary tumor site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H636620624\">",
"      - Targeted therapy (PARP inhibitors)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H636620639\">",
"      Low grade serous neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H636620647\">",
"      - Origins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H636620655\">",
"      - Clinical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H636620662\">",
"      Classification and chemoresponsiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H636620701\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16558\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16558|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/0/15\" title=\"picture 1\">",
"      Fallopian tube intraepithelial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/56/18313\" title=\"picture 2\">",
"      Fallopian tube p53 staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/8/12426\" title=\"picture 3\">",
"      Fallopian tube mucosal proliferations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16558|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/37/18012\" title=\"table 1\">",
"      Tubal neoplasia rrBSO specimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/30/42475\" title=\"table 2\">",
"      Fallopian neoplasia with advanced dz",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=related_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_26_28074="Evaluation and management of fever in the neonate and young infant (less than three months of age)";
var content_f27_26_28074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28074/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28074/contributors\">",
"     Hannah F Smitherman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28074/contributors\">",
"     Charles G Macias, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28074/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28074/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28074/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/26/28074/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/26/28074/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/26/28074/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most neonates and young infants with fever have a benign viral illness, the goal of the evaluation is to identify those children who are at high risk for serious bacterial illness (eg, bacteremia, urinary tract infection, meningitis, bacterial gastroenteritis, pneumonia), and who therefore require empiric antimicrobial therapy and possibly hospitalization.",
"   </p>",
"   <p>",
"    The young febrile infant may demonstrate few, if any, interpretable clues to the underlying illness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/1\">",
"     1",
"    </a>",
"    ]. The limitations of the history and physical examination in neonates and young infants with fever traditionally have led to an aggressive laboratory evaluation, even for patients who were previously healthy, are well-appearing, and have no focal infection. In addition, most of the patients have been admitted to the hospital for antibiotic treatment pending negative cultures. This practice is expensive and can result in iatrogenic morbidity for a substantial number of infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of neonates and young infants younger than three months with fever is discussed below. The definition and etiology of fever in this age group, as well as traditional strategies for evaluating young infants with fever, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28951?source=see_link\">",
"     \"Definition and etiology of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=see_link\">",
"     \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of infants and children age 3 to 36 months is discussed separately. In addition, the diagnosis and treatment of specific infections, including meningitis, pneumonia, and urinary tract infections, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"     \"Fever without a source in children 3 to 36 months of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=see_link\">",
"     \"Urinary tract infections in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history is an essential component of the evaluation of all neonates and young infants with fever (T &ge;38&ordm;C or 100.4&ordm;F). The history should address the following clues to the etiology of the fever:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Associated symptoms (respiratory, gastrointestinal) and behaviors (feeding, irritability, activity)",
"     </li>",
"     <li>",
"      Exposures to sick contacts (siblings, babysitters, day care)",
"     </li>",
"     <li>",
"      Any previous illness, or antibiotic use",
"     </li>",
"     <li>",
"      Birth history, including perinatal factors that suggest an increased risk of vertically transmitted infection such as maternal fever; the mother's group B streptococcus status and prophylaxis; maternal history of sexually transmitted infections such as herpes simplex virus, gonorrhea, and chlamydia; prolonged rupture of membranes, and the infant's nursery course. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H3#H3\">",
"       \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Epidemiology and transmission'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2552?source=see_link&amp;anchor=H2901877#H2901877\">",
"       \"Management of the infant whose mother has received group B streptococcal chemoprophylaxis\", section on 'Overview of management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination must quickly identify the ill-appearing infant who requires immediate resuscitation and treatment. Specific finding to note are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal vital signs, including pulse oximetry, which may be a better predictor of pulmonary infection than respiratory rate [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Toxic appearance including characteristics such as irritability, inconsolability, poor perfusion, poor tone, decreased activity, or lethargy",
"     </li>",
"     <li>",
"      Signs of localized infection such as omphalitis, arthritis, or limb swelling and inflammation, and skin lesions, including skin or mucus membrane lesions, consistent with a herpetic etiology",
"     </li>",
"     <li>",
"      Signs and symptoms associated with bacterial meningitis may be minimal or absent altogether. Subtle clues include altered sleep patterns, decreased oral intake, hyperthermia, hypothermia, or paradoxical irritability (infant more irritable when being held than when lying still). A bulging fontanelle classically presents late in the disease process. Other meningeal signs and symptoms gradually localize to the CNS only as the infant matures. Nuchal rigidity is present in only 27 percent of infants aged zero to six months with bacterial meningitis, compared with 95 percent of patients 19 months or older [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LABORATORY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that have included cohorts of infants younger than three months without an obvious source of fever on physical examination have used a variety of laboratory studies to identify infants at low risk of serious bacterial infection (SBI) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/6-15\">",
"     6-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     WBC count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The white blood cell (WBC) count has been a standard part of the evaluation in virtually all studies of fever in young infants. In most studies, low-risk criteria included a WBC count",
"    <span class=\"nowrap\">",
"     &lt;15,000/microL,",
"    </span>",
"    although in one study, low risk was defined as WBC count",
"    <span class=\"nowrap\">",
"     &lt;20,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/9\">",
"     9",
"    </a>",
"    ], and in another, 5000 to",
"    <span class=\"nowrap\">",
"     15,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/11\">",
"     11",
"    </a>",
"    ]. The number of bands on differential should be no higher than 1.5 x 10(9)",
"    <span class=\"nowrap\">",
"     cells/L",
"    </span>",
"    <span class=\"nowrap\">",
"     (1500/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=see_link\">",
"     \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite its common use, observational studies report that WBC count has poor sensitivity and specificity for identifying bacteremia and meningitis in young infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. For this reason, we suggest that the decision to perform a blood culture or a lumbar puncture not be based solely on the WBC count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4040330\">",
"    <span class=\"h2\">",
"     Blood culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood culture does not help with the immediate assessment of fever but should be obtained routinely in the infant &lt;60 days old or in older infants prescribed empiric antibiotics. Rapid detection of bacterial pathogens is possible with automated blood culture techniques, allowing the identification of positive culture results often within 24 hours. This is particularly helpful in infants managed as outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inflammatory mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no single test is sufficient to rule in or exclude serious bacterial illness (SBI) in febrile young infants, evidence from observational studies suggests that elevation of procalcitonin (PCT) or C-reactive protein (CRP) level mays be a better marker of SBI than white blood cell count (WBC), and PCT may best indicate invasive bacterial illness (IBI):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter observational study of 1112 well-appearing febrile infants (26 percent with a SBI [urinary tract infection, bacterial gastroenteritis, bacteremia, or bacterial meningitis] and 2 percent with an IBI [bacteremia or bacterial meningitis]), a PCT &ge;0.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      was the only marker independently associated with IBI (adjusted OR 22) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/18\">",
"       18",
"      </a>",
"      ]. A PCT &lt;0.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      was better than WBC, absolute neutrophil count, and C-reactive protein for ruling out an IBI and reduced the posttest probability of IBI to 0.4 percent among infants with fever and normal urine dipstick results. A CRP &le;20",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      and &gt;40",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      was similar in accuracy for ruling out or ruling in SBI (most commonly, a urinary tract infection), respectively, when compared to a PCT level of &lt;0.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (rule out SBI) or &ge;2",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (rule in SBI). Either procalcitonin or CRP measurements were superior to WBC in accuracy for identifying young febrile infants with SBI.",
"     </li>",
"     <li>",
"      In a separate analysis of well-appearing febrile infants included in the above study who had a urine dipstick, CRP and procalcitonin level obtained, a Lab-score was computed as follows: 2 points for PCT &ge;0.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or CRP &ge;40",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      4 points for PCT &ge;2",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or CRP &ge;100",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      and 1 point for positive urine dipstick (either positive leukocyte esterase, positive nitrites, or both) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/19\">",
"       19",
"      </a>",
"      ]. A Lab-score &ge;3 had a sensitivity of 52 percent and specificity of 95 percent for SBI (1012 febrile infants), a sensitivity of 70 percent and specificity of 84 percent for IBI (1098 infants), and post-test probabilities of 80 percent for SBI and 8 percent for IBI. &nbsp;",
"     </li>",
"     <li>",
"      An observational study of 234 young infants found that a cutoff value for procalcitonin of 0.12",
"      <span class=\"nowrap\">",
"       nanograms/mL",
"      </span>",
"      had a sensitivity of 95 percent (95% CI 83-99 percent), a specificity of 26 percent (95% CI 20-32 percent), and a negative predictive value of 96 percent (95% CI 85-99 percent) for serious bacterial illness [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An observational study of 271 young infants found that young infants with SBI and immunized febrile young infants had higher median procalcitonin levels than unimmunized febrile young infants without serious bacterial infection (0.53, 0.29, and 0.17",
"      <span class=\"nowrap\">",
"       nanograms/mL,",
"      </span>",
"      respectively). In this study, a cut off value of 0.12",
"      <span class=\"nowrap\">",
"       nanograms/mL",
"      </span>",
"      had a sensitivity of 96 percent (95% CI 83-99 percent), a specificity of 23 percent (95% CI 18-29 percent), and a negative predictive value of 96 percent (95% CI 86-99 percent) for detecting serious bacterial infection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, individual and combined measurements of CRP and PCT appear to complement and enhance the ability to detect SBI and IBI in young febrile infants when used along with urine dipstick, WBC, and ANC. However, use of these markers alone has limited ability to exclude SBI or IBI.",
"   </p>",
"   <p>",
"    In most clinical settings, PCT has limited availability. In addition, questions exist regarding the reliability of the bedside procalcitonin assay used in these studies because of variation in results by age, type of infection, and pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/22\">",
"     22",
"    </a>",
"    ]. Further study is needed to better define the utility of procalcitonin for identifying febrile young infants (under 90 days of age) with serious bacterial infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Urine examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that a urinalysis and urine culture be obtained because the incidence of urinary tract infection (UTI) is high among febrile young infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/11,23,24\">",
"     11,23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=see_link\">",
"     \"Epidemiology and risk factors for urinary tract infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A urine specimen for culture should be obtained by urethral catheterization or suprapubic aspiration, as bag collections frequently are contaminated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=see_link&amp;anchor=H15#H15\">",
"     \"Urinary tract infections in newborns\", section on 'Urine collection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42886?source=see_link\">",
"     \"Urine collection techniques in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A negative urine dipstick or urinalysis alone does not exclude UTI; pyuria is absent on initial urinalysis in up to 20 percent of febrile infants with pyelonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, urine culture should be performed on all specimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Stool examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all studies of febrile neonates and young infants included evaluation of the stool for WBCs in patients with diarrhea. One study found the presence of &ge;5 WBCs per high-power field to be a predictor of occult Salmonella infection, including bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/11\">",
"     11",
"    </a>",
"    ]. However, a Wright stain of the stool for WBCs may not be readily available. A stool culture is suggested when there is blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucus in the stool or for the infant with diarrhea when a Wright stain is not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that lumbar puncture always be performed in febrile infants with the following indications (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Evaluation and management'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &le;28 days",
"     </li>",
"     <li>",
"      Ill appearance",
"     </li>",
"     <li>",
"      Diagnostic evaluation identifies a high risk for bacterial infection (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=see_link\">",
"       \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prior to administration of empiric antibiotics",
"     </li>",
"     <li>",
"      Clinically evident invasive infection (eg, cellulitis, abscess, mastitis, omphalitis, osteomyelitis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Severe SSTI'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cerebrospinal fluid should be sent for cell count, glucose, protein, and bacterial culture. In addition, viral studies (viral culture, polymerase chain reaction [PCR]) should be sent if the clinical picture suggests viral meningitis (",
"    <a class=\"graphic graphic_table graphicRef66525 \" href=\"UTD.htm?18/25/18845\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=see_link&amp;anchor=H17#H17\">",
"     \"Viral meningitis: Clinical features and diagnosis in children\", section on 'CSF studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several observational studies suggest that infants at low risk of SBI can be identified without performing a lumbar puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/6,7,11,13,14\">",
"     6,7,11,13,14",
"    </a>",
"    ]. Based on these reports, some consider lumbar puncture optional in a generally well-appearing infant who is over 28 days of age, particularly if the infant has a low-grade fever [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the significant morbidity and mortality associated with bacterial meningitis may outweigh the low incidence of this infection in making the decision whether or not to perform a lumbar puncture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=see_link\">",
"     \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that lumbar puncture be performed if empiric antibiotics are prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/3\">",
"     3",
"    </a>",
"    ]. Otherwise, if the child returns for further evaluation and lumbar puncture at that time reveals CSF pleocytosis, it will not be clear whether a negative culture result is due to partially treated bacterial meningitis or aseptic meningitis. This uncertainty may result in the infant receiving an unnecessary course of antibiotics.",
"   </p>",
"   <p>",
"    Seizures may be a sign of meningitis, and we recommend that a lumbar puncture be performed in all neonates and young infants who have had a seizure. Appropriate CSF studies to identify possible viral etiologies may be useful diagnostically (",
"    <a class=\"graphic graphic_table graphicRef66525 \" href=\"UTD.htm?18/25/18845\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=see_link&amp;anchor=H18#H18\">",
"     \"Viral meningitis: Clinical features and diagnosis in children\", section on 'Virology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all studies of febrile neonates and young infants have included a chest radiograph as part of the initial evaluation. A chest radiograph is helpful in identifying a source of infection in infants with at least one clinical sign of pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/25\">",
"     25",
"    </a>",
"    ]. This was illustrated in a meta-analysis of 617 febrile infants less than three months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/27\">",
"     27",
"    </a>",
"    ]. All 361 infants who had no clinical evidence of pulmonary disease (defined as respiratory rate &gt;50",
"    <span class=\"nowrap\">",
"     breaths/min,",
"    </span>",
"    rales, rhonchi, retractions, wheezing, coryza, grunting, stridor, nasal flaring, or cough) had normal chest radiographs. In contrast, 85 of 256 infants (33 percent) with at least one of these signs had an abnormal chest radiograph.",
"   </p>",
"   <p>",
"    Even when the chest radiograph reveals pneumonia, a viral etiology is most likely, given that nonbacterial pneumonias comprise the majority of cases of pneumonia in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/28\">",
"     28",
"    </a>",
"    ]. A bacterial process is more likely if alveolar disease (consolidation and air bronchograms) or bronchopneumonia (diffuse bilateral pattern with increased peribronchial markings and small fluffy infiltrates) is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cautious approach to neonates (0 to 28 days) and young infants (29 to 90 days) with fever is prudent, given the risk and potentially adverse consequences of unrecognized",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    untreated serious bacterial infection (SBI). Multiple approaches to the evaluation of these infants, with varying inclusion and exclusion criteria, have been proposed and studied, including protocols from Boston, Philadelphia, and Rochester [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. While these approaches have a high negative predictive value (ability to remove patients with SBI from the low-risk group), each suffers from a relatively low positive predictive value, resulting in many infants undergoing unnecessary laboratory testing, hospitalization, and exposure to unnecessary antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=see_link\">",
"     \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The predictors of SBI used to classify febrile infants into risk subsets aid in the assessment of risk, but they do not eliminate risk. There is a lack of definitive data to guide patient evaluation, and some categories that define high-risk groups such as age and white blood cell (WBC) count are arbitrary. Consequently, each patient and each clinical situation must be evaluated individually. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=see_link\">",
"     \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the use of evidence-based guidelines could help standardize care among, not only individual physicians, but various institutions as well. As an example, outcomes for well-appearing febrile infants cared for in four hospitals, including a children&rsquo;s hospital, were assessed before (4524 febrile episodes) and after (2987 febrile episodes) the implementation of an evidence-based care process model (EB-CPM) that was derived from the Rochester criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. EB-CPM implementation was associated with significantly increased adherence to recommended diagnostic testing (13 percent increased measurement of complete blood count, urinalysis, blood and urine culture; 8 percent increase in viral testing for admitted infants), recommended antibiotic selection (15 percent increased use of recommended antibiotics), a 16 hour decrease in hospital length of stay for admitted patients, and a significantly lower cost per admitted infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neonates (0 to 28 days)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available guidelines and approaches to fever in young infants do not perform well in neonates 28 days of age and younger compared with older infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/1\">",
"     1",
"    </a>",
"    ]. Consequently, most experts recommend that all neonates with a rectal temperature &ge;38&ordm;C have blood, urine, and CSF cultures performed regardless of clinical appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. A chest radiograph should be obtained in those with any sign or symptom of pulmonary disease. These neonates should be admitted to the hospital and treated with empiric antibiotics (",
"    <a class=\"graphic graphic_table graphicRef55679 \" href=\"UTD.htm?1/16/1292\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=see_link&amp;anchor=H6#H6\">",
"     \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\", section on 'Limitations in neonates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious bacterial illness is present in approximately 12 percent of febrile neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/33\">",
"     33",
"    </a>",
"    ]. Group B Streptococcus, a common pathogen in this age group, causes high rates of meningitis (39 percent) and sepsis (9 percent). Prior to routine antibiotic administration to intrapartum mothers and to febrile neonates, the case fatality rate approached 50 percent in babies with early onset group B Streptococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/34\">",
"     34",
"    </a>",
"    ]. Other organisms that cause SBI in neonates include Escherichia coli and other gram negative rods, enterococcus, and Listeria monocytogenes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In addition, Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis cause disease in the slightly older neonate.",
"   </p>",
"   <p>",
"    Because of the high rates of serious bacterial infection and high risk of mortality if untreated, we recommend empiric treatment with antibiotics.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     Ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or ampicillin and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    are potential regimens that will provide empiric coverage for these organisms until culture results are available (",
"    <a class=\"graphic graphic_table graphicRef55679 \" href=\"UTD.htm?1/16/1292\">",
"     table 2",
"    </a>",
"    ). The combination of ampicillin and cefotaxime is preferred in regions where there are high rates of gentamicin-resistant organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28951?source=see_link\">",
"     \"Definition and etiology of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Acyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    should not be used routinely in the management of febrile neonates, those who are ill-appearing, have mucocutaneous vesicles, have a maternal history of genital herpesvirus (HSV) infection, or have seizures should be treated with acyclovir (60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided three times daily). In addition, elevated liver enzymes may be an early indicator of disseminated HSV in neonates less than two weeks of age. Controversy exists regarding the use of empiric acyclovir in neonates who have CSF pleocytosis without other clinical features suggestive of HSV. We suggest that such patients receive acyclovir empirically pending the results of bacterial CSF culture and CSF HSV DNA polymerase chain reaction (PCR). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=see_link&amp;anchor=H4#H4\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'Acyclovir therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H4#H4\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cultures of skin vesicles (if present), oropharynx, conjunctivae, urine, blood, stool, and cerebrospinal fluid for HSV should be obtained before the initiation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    . HSV antigen may be detected using direct fluorescent antibody (DFA) tests of scrapings from the base of vesicles. In addition, CSF should be sent for HSV DNA polymerase chain reaction (PCR). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28951?source=see_link\">",
"     \"Definition and etiology of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H310880\">",
"    <span class=\"h2\">",
"     Ill-appearing infants (29 to 90 days)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who are ill-appearing, have an abnormal cry, or temperatures &ge;38.5&ordm;C have a higher risk of SBI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Because up to 45 percent of ill-appearing young infants may have SBI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/1\">",
"     1",
"    </a>",
"    ], such infants should undergo the following treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Full laboratory evaluation including blood, urine, and CSF",
"     </li>",
"     <li>",
"      Chest radiograph if signs or symptoms of pulmonary disease are present (respiratory rate &gt;50",
"      <span class=\"nowrap\">",
"       breaths/min,",
"      </span>",
"      rales, rhonchi, retractions, wheezing, coryza, grunting, stridor, nasal flaring, or cough).",
"     </li>",
"     <li>",
"      Empiric antibiotic therapy (with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ), regardless of the initial laboratory results. Empiric therapy should also be adjusted based on specific clinical findings as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       Ampicillin",
"      </a>",
"      (to cover Listeria up to six to eight weeks of age)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      should be given to those infants with evidence of soft tissue infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Severe SSTI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      should be given to those infants with CSF pleocytosis to treat meningitis caused by S. pneumoniae that is not susceptible to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      , and in infants 29 to 60 days of age,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      should also be given to cover Listeria monocytogenes (",
"      <a class=\"graphic graphic_table graphicRef55679 \" href=\"UTD.htm?1/16/1292\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link\">",
"       \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospital admission",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H310985\">",
"    <span class=\"h2\">",
"     Well-appearing infants",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H311038\">",
"    <span class=\"h3\">",
"     29 to 60 days",
"    </span>",
"    &nbsp;&mdash;&nbsp;For well-appearing infants with a rectal temperature &ge;38.0&ordm;C, laboratory testing is necessary to help determine which patients may be at high risk for a serious bacterial illness (SBI) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/11\">",
"     11",
"    </a>",
"    ]. A complete history and physical examination with appropriate laboratory evaluation including CBC, blood culture, urinalysis and culture, and CSF for cell count and culture should be performed in most patients. Infants without CSF pleocytosis, a WBC count 5000 to",
"    <span class=\"nowrap\">",
"     15,000/microL,",
"    </span>",
"    and a normal urinalysis are at low risk for an SBI.",
"   </p>",
"   <p>",
"    Some clinicians may elect to perform fewer laboratory tests. There are, however, no guidelines for the minimal evaluation of fever in well-appearing infants ages 29 to 60 days. The following factors should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary tract infections (UTIs) are common in this age group, particularly in uncircumcised boys and in girls [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/24\">",
"       24",
"      </a>",
"      ]. Consideration always should be given to performing a urinalysis with culture.",
"     </li>",
"     <li>",
"      A WBC count 5000 to",
"      <span class=\"nowrap\">",
"       15,000/microL",
"      </span>",
"      with less than 1500",
"      <span class=\"nowrap\">",
"       bands/microL",
"      </span>",
"      suggests a lower risk of SBI.",
"     </li>",
"     <li>",
"      A stool culture should be performed if diarrhea is present.",
"     </li>",
"     <li>",
"      Lumbar puncture may not be necessary in some well-appearing infants who have knowledgeable caregivers, reliable transportation, and well-established follow-up. However, a lumbar puncture should always be performed whenever empiric antibiotics are prescribed.",
"     </li>",
"     <li>",
"      A chest radiograph should be obtained in infants with at least one clinical sign of pulmonary disease (respiratory rate &gt;50",
"      <span class=\"nowrap\">",
"       breaths/min,",
"      </span>",
"      rales, rhonchi, retractions, wheezing, coryza, grunting, stridor, nasal flaring, or cough) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/27,40\">",
"       27,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants 29 to 60 days of age with CSF pleocytosis or a peripheral WBC",
"    <span class=\"nowrap\">",
"     &ge;20,000/microL",
"    </span>",
"    should be admitted to the hospital for treatment with empiric parenteral antibiotics. Many clinicians may also prefer to admit infants with WBC",
"    <span class=\"nowrap\">",
"     &le;5000/microL",
"    </span>",
"    and WBC",
"    <span class=\"nowrap\">",
"     &ge;15,000/microL.",
"    </span>",
"    We also suggest that those with an abnormal urinalysis be treated with parenteral antibiotics as inpatients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=see_link\">",
"     \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some experts treat well-appearing infants with an abnormal urinalysis with parenteral antibiotics as outpatients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Limited data from a retrospective review of the hospital course of febrile infants &lt;60 days of age with UTI demonstrated that progression of illness was unlikely and lends some support to this strategy as long as the infant is well-appearing, does not have a high risk past medical history, and has normal peripheral band and absolute neutrophil counts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple prospective studies have reported that infants who are at low risk of SBI based on history, physical examination, and whatever laboratory testing has been performed can be safely managed as outpatients. Reliable follow-up must be arranged within 24 hours (either by phone or by return visit to the clinician). If the social situation suggests that follow-up within 24 hours is problematic (eg, transportation problems or other concerns regarding parental adherence), then the infant should be admitted to the hospital. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=see_link&amp;anchor=H2#H2\">",
"     \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\", section on 'Traditional strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants who are followed as outpatients may be treated presumptively with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in a single dose), pending culture results. In making the decision whether or not to prescribe empiric antibiotic therapy, the clinician must consider both the potentially severe risk of not treating an SBI as well as the more common but typically less severe risks associated with parenteral antibiotic administration. We recommend that CSF for culture be obtained if antibiotics are given empirically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H311147\">",
"    <span class=\"h3\">",
"     61 to 90 days",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the incidence of serious bacterial infection (SBI) among infants 61 to 90 days of age with fever (as compared with younger infants) on which to base definitive guidelines are limited. The risk of SBI for this age group may be similar to that for older febrile infants. In a prospective observational study (conducted after the initiation of routine immunization of infants with conjugated pneumococcal vaccine) describing febrile infants 57 to 180 days of age, there was no significant difference in the incidence of SBI between those who were 57 to 89 days of age and those who were older [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"     \"Fever without a source in children 3 to 36 months of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since infants less than three months of age have not yet been fully immunized against pneumococcus and Haemophilus influenzae type b, most experts recommend a CBC, urinalysis, and cultures of blood and urine be obtained in those who are well-appearing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link&amp;anchor=H26#H26\">",
"     \"Fever without a source in children 3 to 36 months of age\", section on 'Well-appearing'",
"    </a>",
"    .) Those who have signs of pulmonary disease should have a chest radiograph as well.",
"   </p>",
"   <p>",
"    Despite its poor ability to identify young infants with bacteremia or meningitis, a WBC outside of the normal range of 5000 to",
"    <span class=\"nowrap\">",
"     15,000/microL",
"    </span>",
"    suggests the need for lumbar puncture followed by treatment with parenteral antibiotics until all cultures are final (",
"    <a class=\"graphic graphic_table graphicRef55679 \" href=\"UTD.htm?1/16/1292\">",
"     table 2",
"    </a>",
"    ). For outpatient therapy in patients with normal cerebrospinal fluid (CSF) and urinalysis,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is the preferred drug because of its antimicrobial spectrum and long duration of action. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'WBC count'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Ill-appearing infants with an abnormal urinalysis should receive parenteral antibiotics after obtaining CSF and be admitted to the hospital. However, well-appearing infants, over two months of age, can be treated orally as long as oral intake is tolerated without obtaining CSF. The choice of antibiotic is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Oral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with infants 29 to 60 days of age, the clinician must consider the risk of not treating an SBI as well as the risks associated with parenteral antibiotic administration in deciding whether or not to prescribe empiric antibiotic therapy (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in a single dose). We suggest that CSF be obtained if empiric antibiotics are prescribed (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Lumbar puncture'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Follow-up for outpatient treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-appearing infants ages 29 to 90 days who are sent home must have follow-up within 24 hours either by phone or by visit, at which time preliminary culture results (if obtained) are reviewed. Patients who received parenteral antibiotics at the initial visit should return for a second intramuscular dose (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    pending final culture results.",
"   </p>",
"   <p>",
"    Any of the following circumstances warrants extensive evaluation and hospitalization for empiric antibiotic therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , or other antibiotics, as indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Any deterioration in clinical status or worsening of fever",
"     </li>",
"     <li>",
"      A positive blood culture not thought to be a contaminant",
"     </li>",
"     <li>",
"      A positive urine culture in an infant who remains febrile",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For an infant with a positive urine culture who is afebrile and well-appearing less than 24 hours after parenteral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , it may be reasonable to give a second dose of parenteral ceftriaxone at 24 hours and continue outpatient follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=see_link\">",
"     \"Urinary tract infections in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Discharge criteria for admitted patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The length of hospitalization depends upon the clinical course of the patient and the type of culture system in use. &nbsp;Early discharge is feasible in hospitals with continuously monitored blood culture instruments, These systems identify between 77 and 87 percent of all cultures with pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] and 95 percent of critical pathogens (eg, S. pneumoniae, Salmonella and other Enterobacteriaceae, N. meningitidis, groups A and B streptococcus) within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Admitted patients over 28 days of age, who remain well-appearing during hospitalization and become afebrile are eligible for discharge at 36 hours of negative cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/29\">",
"     29",
"    </a>",
"    ].&nbsp;In addition, 24 hour discharge may be appropriate for well-appearing&nbsp;patients who have positive viral testing regardless of the presence of fever. Patients sent home before bacterial cultures have been negative for 48 hours must have follow up within 24 hours either by phone or by visit, at which time preliminary culture results are reviewed. If antibiotics were given in the hospital and diagnostic testing do not identify a viral etiology, then the child should receive two additional doses of antibiotics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) until all cultures are final and negative.",
"   </p>",
"   <p>",
"    For some admitted infants, fever may persist after cultures are negative at 48 hours. For the patient whose clinical condition has improved, a period of observation in the hospital off antimicrobial therapy is a reasonable option. The child who remains ill or who does not improve as expected should be carefully reevaluated, and further testing, consultation, and treatment options should be pursued.",
"   </p>",
"   <p>",
"    Of note, neonates (0-28 days of age) by definition are not low risk and would not be eligible for early discharge. These patients typically receive inpatient care and parenteral antibiotics until all cultures are negative for at least 48 hours. Furthermore, initial treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    implies significant clinical concern for herpes infection. It would seem prudent then to continue to treat the infant with acyclovir until the PCR result of CSF specimen is available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=see_link&amp;anchor=H4#H4\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'Acyclovir therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of early discharge criteria has been associated with reduced length of stay. As an example, implementation of a care plan that allowed discharge at 24 hours for infants with positive viral testing for enterovirus or respiratory viruses, other than rhinovirus, (eg, respiratory syncytial virus, influenza) and negative bacterial cultures",
"    <strong>",
"     or",
"    </strong>",
"    discharge at 36 hours if both viral testing and bacterial cultures were negative resulted in a clinically significant decrease in length of stay across a large hospital system without an increase in readmissions for bacterial illness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIFFICULT CLINICAL SITUATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinical situations arise that do not fit neatly into treatment guidelines. Until more definitive information becomes available, these circumstances should be considered on an individual basis, using clinical judgment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15639137\">",
"    <span class=\"h2\">",
"     Dry or traumatic lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the decision is made to perform a lumbar puncture (LP), every reasonable attempt should be made to obtain cerebrospinal fluid (CSF) for studies and culture. However, this cannot always be accomplished and either no CSF (dry LP) or bloody CSF (traumatic LP) may be obtained. In this circumstance, at a minimum, cultures of blood and urine should be obtained.",
"   </p>",
"   <p>",
"    If the LP is traumatic, the tube in which the CSF is clearest should be sent for a cell count. For patients with a peripheral white blood cell (WBC) count that is in the normal range, one rule of thumb is to subtract one WBC for every 500 to 1500 red blood cells. A predicted CSF WBC count can also be used and its calculation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=see_link&amp;anchor=H11#H11\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\", section on 'Predicted WBC after traumatic tap'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility of meningitis cannot be excluded when the CSF cell count is not available or is not interpretable. In this situation, the infant should be admitted and treated with meningitic doses of antibiotics until the CSF culture is negative at 48 hours or the clinical picture warrants discharge.",
"   </p>",
"   <p>",
"    When no CSF culture is obtained, negative blood and urine culture results in a baby who does well would be reassuring, although the true incidence of meningitis in patients who have negative blood and urine cultures is not known. A repeat lumbar puncture after admission, or observing the infant in the hospital off antibiotics after the cultures are negative at 48 hours, are two acceptable approaches, especially in infants under 29 days of age.",
"   </p>",
"   <p>",
"    In contrast, the infant with a traumatic LP who has done well and has negative blood, urine, and CSF cultures at 48 hours typically does not require a repeat lumbar puncture. In selected instances, infants over 28 days of age may be discharged without a repeat LP or observation off antibiotics if they are well-appearing and afebrile in addition to having negative blood and urine cultures.",
"   </p>",
"   <p>",
"    However, a repeat lumbar puncture should be performed if either the blood or urine culture is positive in patients with a dry LP because the finding of CSF pleocytosis may necessitate a prolonged course of parenteral antibiotics, depending upon the organism isolated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=see_link&amp;anchor=H32#H32\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'Duration of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H29#H29\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Patient on antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A young infant on prophylactic antibiotics, usually for a urinary tract abnormality, may have a serious bacterial illness masked by negative culture results. CBC, UA, CSF cell count, and cultures of blood, urine, and CSF should be obtained with the understanding that regardless of the laboratory evaluation, these patients cannot be classified as \"low risk\" for serious bacterial infection (SBI), since they have an underlying condition that places them at risk for SBI. Neonates should be admitted to the hospital and treated empirically with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    or ampicillin and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    , at least until cultures have been negative for 48 hours. For well-appearing infants &ge;29 days, it would be reasonable to consider admission to the hospital and empiric antibiotic therapy, or at least observation in the hospital off of antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Concomitant viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the concern for SBI, most young infants with fever have a viral illness. The presence of upper respiratory symptoms does not rule in a viral etiology, nor conversely rule out an SBI. However, infants with a \"recognizable viral syndrome,\" such as bronchiolitis, croup, varicella, or stomatitis, have a markedly lower risk for bacteremia, although UTI remains a significant concomitant infection in those with bronchiolitis and influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid diagnostic tests for the detection of viral neuraminidase are commercially available for influenza A and B viruses and can be used for rapid point of care testing. However, test performance is variable. False positive results occur and are of particular concern if rapid influenza testing is used to limit further laboratory evaluation in young febrile infants. As a result, rapid influenza testing should only be relied upon for clinical management during the time of regional high prevalence for influenza infection, since high prevalence will raise the positive predictive value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Laboratory diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a multicenter trial of 844 febrile infants &le;60 days of age who were tested for influenza, a significantly lower rate of serious bacterial illness (SBI) was noted in the 123 infants who were influenza-positive compared with the 721 infants who were influenza-negative (2.5 percent versus 11.7 percent, relative risk 0.19 [95% CI 0.06-0.59]) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/49\">",
"     49",
"    </a>",
"    ]. The three infants with SBI in the influenza-positive group all had a urinary tract infection (UTI); none had bacteremia or meningitis. In contrast, SBIs in influenza-negative patients included 77 with UTIs, 16 with bacteremia, and 6 with meningitis.",
"   </p>",
"   <p>",
"    Although bacteremia was not identified in any of the 123 febrile infants with influenza, we suggest that a complete blood count (CBC) with differential, blood culture, urinalysis, urine culture, and, in children with clinical signs of pneumonia, a chest radiograph be obtained. If the CBC and urinalysis do not suggest bacterial infection, lumbar puncture can be omitted in well-appearing febrile infants who are older than 28 days of age, have a positive rapid influenza test, and no evidence of bacterial infection on physical examination. This approach should only be considered if the rapid influenza test in use has high specificity and is obtained during a time of high prevalence of influenza infection in the region, thereby maximizing the positive predictive value.",
"   </p>",
"   <p>",
"    Parents of infants more than 28 days of age who are discharged home from the emergency department should understand that worsening respiratory distress, ill appearance, or inability to feed warrant emergent return for medical care. In addition, these patients should have assured follow-up with their primary care provider within 24 hours for possible worsening disease. As an example, rapidly progressive Staphylococcus aureus pneumonia has been described in infants and children with influenza and should be suspected if other members of the family have had or have S. aureus infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Bacterial coinfection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H19#H19\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Clinical spectrum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current evidence is insufficient to identify the risk of SBI in febrile neonates &le;28 days of age with influenza infection, as only 36 such patients were in the above trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/49\">",
"     49",
"    </a>",
"    ]. Extrapolation from studies of febrile neonates with concomitant RSV infection suggests that those with influenza infection may remain at high risk for an SBI and should undergo a full evaluation followed by inpatient observation with antibiotic therapy. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Bronchiolitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Bronchiolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple retrospective and prospective observational studies demonstrate that the incidence of SBI is 1.1 to 7 percent among febrile infants with bronchiolitis as opposed to 10 to 17 percent in high risk febrile infants without bronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/47,50-61\">",
"     47,50-61",
"    </a>",
"    ]. However, the risk of SBI among neonates (0 to 28 days of age) is substantial and does not appear to be altered by the presence of RSV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/47,61\">",
"     47,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    UTI is the most common SBI seen in febrile infants with bronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/60\">",
"     60",
"    </a>",
"    ]. Bacteremia may be found in up to 1 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/47\">",
"     47",
"    </a>",
"    ]. No cases of meningitis have been described in febrile infants with concomitant clinical bronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest that it may be reasonable to limit laboratory testing in well-appearing febrile infants older than 28 days of age with bronchiolitis to CBC, blood culture, urinalysis, and urine culture. If the CBC and urinalysis do not suggest bacterial infection, then these children may be managed without antibiotics according to the degree of illness caused by their bronchiolitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=see_link&amp;anchor=H162664498#H162664498\">",
"     \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\", section on 'Indications for hospitalization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Febrile neonates (0 to 28 days) with bronchiolitis remain at high risk for an SBI and should have a full evaluation and inpatient observation with antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute otitis media (AOM) is diagnosed infrequently in neonates and young infants. Nevertheless, the infant who presents with otitis media, with or without fever, can present a diagnostic and management challenge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link&amp;anchor=H19#H19\">",
"     \"Acute otitis media in children: Diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Rochester [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/11\">",
"     11",
"    </a>",
"    ] and Boston criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/9\">",
"     9",
"    </a>",
"    ] specifically exclude patients with ear infections from low-risk groups, and the Philadelphia protocol only considers low-risk those cases with an \"unremarkable exam\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/8\">",
"     8",
"    </a>",
"    ]. On the other hand, one study found that none of the 13 infants excluded from the low-risk group for only otitis media had systemic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/12\">",
"     12",
"    </a>",
"    ], and in a second report no infant excluded from the low-risk group because of otitis media had a systemic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=see_link\">",
"     \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, a report of 130 patients 60 days and younger with AOM confirmed by tympanocentesis found that the presence of AOM did not predict a higher risk for SBI in either febrile or afebrile patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/62\">",
"     62",
"    </a>",
"    ]. None of the afebrile infants with AOM or the febrile infants who were otherwise determined to be at low risk developed an SBI. On the other hand, 14 percent of high-risk infants with AOM also had a serious bacterial illness.",
"   </p>",
"   <p>",
"    Finally, in a study of 40 infants zero to eight weeks of age with isolated otitis media who underwent a full sepsis evaluation and tympanocentesis, all afebrile infants had negative cultures of blood, urine, and CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/26/28074/abstract/63\">",
"     63",
"    </a>",
"    ]. Two febrile infants had an SBI.",
"   </p>",
"   <p>",
"    These findings suggest that febrile infants with AOM should be evaluated and managed similarly to febrile infants without AOM. The decision to forego a full sepsis evaluation in afebrile infants with AOM should be made with caution. The practitioner must consider the possibility of masking an SBI and the difficult situation that will arise if the infant becomes febrile and ill-appearing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       \"Patient information: Fever in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"       \"Patient information: Fever in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risk and potentially adverse consequences of unrecognized",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    untreated serious bacterial infection (SBI), a cautious approach to neonates (0 to 28 days) and young infants (29 to 90 days) with fever (T &ge;38&ordm;C or 100.4&ordm;F) is prudent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28951?source=see_link\">",
"     \"Definition and etiology of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Definitive data to guide patient evaluation are lacking, and some categories that define high-risk groups such as age and white blood cell (WBC) count are arbitrary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=see_link\">",
"     \"Strategies for the evaluation of fever in neonates and infants (less than three months of age)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consequently, each patient and each clinical situation must be evaluated individually. Bearing in mind that the predictors of SBI used to classify febrile infants into risk subsets aid in the assessment of risk, but do not eliminate risk, we offer the following recommendations:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Neonates (0 to 28 days)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that all neonates with a rectal temperature &ge;38&ordm;C have blood, urine, and CSF cultures performed regardless of clinical appearance. We recommend a chest radiograph be obtained in those with any sign or symptom of pulmonary disease. We recommend that these neonates be admitted to the hospital (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Because of the high rates of serious bacterial infection and high risk of mortality if untreated, we recommend empiric treatment with antibiotics (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef55679 \" href=\"UTD.htm?1/16/1292\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Neonates (0 to 28 days)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       Ampicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      or ampicillin and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      are potential regimens that will provide empiric coverage for these organisms until culture results are available (",
"      <a class=\"graphic graphic_table graphicRef55679 \" href=\"UTD.htm?1/16/1292\">",
"       table 2",
"      </a>",
"      ). The combination of ampicillin and cefotaxime is preferred in regions where there are high rates of gentamicin-resistant organisms. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Neonates (0 to 28 days)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants &le;28 days who are ill-appearing and lethargic, demonstrate mucocutaneous vesicles, have had seizures, display a CSF pleocytosis, or exhibit elevated liver transaminases may have a CNS or disseminated herpes simplex virus (HSV) infection. In this select population of infants, we suggest initiating treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided three times daily) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients who are not initially treated with acyclovir, we suggest adding it if the bacterial cultures remain negative at 48 to 72 hours, and the patient has not improved clinically (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Routine use of acyclovir is not indicated in the management of febrile neonates. Laboratory studies to confirm the diagnosis of HSV should be sent prior to the initiation of acyclovir. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Neonates (0 to 28 days)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H311933\">",
"    <span class=\"h2\">",
"     Ill-appearing infants (29 to 90 days)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that infants who are ill-appearing have a full laboratory evaluation including blood, urine, and CSF cultures and receive parenteral antibiotics. Those who have signs of pulmonary disease should also receive a chest radiograph. We recommend that these patients receive empiric antibiotic therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      and be admitted to the hospital for ongoing parenteral antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H310880\">",
"       'Ill-appearing infants (29 to 90 days)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric antibiotic therapy should also be adjusted based on specific clinical findings as follows (see",
"      <a class=\"local\" href=\"#H310880\">",
"       'Ill-appearing infants (29 to 90 days)'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      should be given to those infants with evidence of soft tissue infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Severe SSTI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      should be given to those infants with CSF pleocytosis to treat meningitis caused by S. pneumoniae that is not susceptible to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      and, in infants 29 to 60 days of age,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      should also be given to cover Listeria monocytogenes (",
"      <a class=\"graphic graphic_table graphicRef55679 \" href=\"UTD.htm?1/16/1292\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link\">",
"       \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H311941\">",
"    <span class=\"h2\">",
"     Well-appearing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H311948\">",
"    <span class=\"h3\">",
"     Infants 29 to 60 days of age",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that well-appearing infants 29 to 60 days of age with a rectal temperature &ge;38.0&ordm;C undergo a complete history and physical examination with appropriate laboratory evaluation including CBC, blood culture, urinalysis and culture, and CSF for cell count and culture. Although lumbar puncture may not be necessary in some well-appearing infants, including those with bronchiolitis or a positive rapid test for influenza, we recommend that lumbar puncture be performed if empiric antibiotics are prescribed, including in infants who have an abnormal urinalysis or otitis media. A stool culture is suggested if diarrhea is present. (See",
"      <a class=\"local\" href=\"#H311038\">",
"       '29 to 60 days'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that a chest radiograph be obtained only in infants with at least one clinical sign of pulmonary disease (respiratory rate &gt;50",
"      <span class=\"nowrap\">",
"       breaths/minute,",
"      </span>",
"      rales, rhonchi, retractions, wheezing, coryza, grunting, stridor, nasal flaring, or cough). (See",
"      <a class=\"local\" href=\"#H311038\">",
"       '29 to 60 days'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants who have an abnormal urinalysis, CSF pleocytosis, or an abnormal chest radiograph require presumptive antibiotic therapy (",
"      <a class=\"graphic graphic_table graphicRef55679 \" href=\"UTD.htm?1/16/1292\">",
"       table 2",
"      </a>",
"      ). Infants with pneumonia or meningitis should be admitted to the hospital. We suggest that infants under 60 days of age with an abnormal urinalysis also be admitted for a period of observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H311038\">",
"       '29 to 60 days'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants 29 to 60 days of age who are well-appearing and have a normal laboratory evaluation and chest radiograph, when one is performed, can be sent home as long as reliable follow-up within 24 hours can be arranged (either by phone or by return visit to the clinician). We suggest treatment with parenteral antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in a single dose) is preferred because of its antimicrobial spectrum and long duration of action. This recommendation emphasizes the small but potentially severe risk of not treating an SBI as opposed to the more common but typically less severe risks associated with parenteral antibiotic administration. We suggest that CSF be obtained if antibiotics are given empirically. (See",
"      <a class=\"local\" href=\"#H311038\">",
"       '29 to 60 days'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H311955\">",
"    <span class=\"h3\">",
"     Infants 61 to 90 days of age",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that a CBC, urinalysis, and cultures of blood and urine be obtained in well-appearing infants. Those who have signs of pulmonary disease should receive a chest radiograph as well. In addition, WBC outside of the normal range of 5000 to",
"      <span class=\"nowrap\">",
"       15,000/microL",
"      </span>",
"      suggests the need for lumbar puncture followed by treatment with parenteral antibiotics until all cultures are final (",
"      <a class=\"graphic graphic_table graphicRef55679 \" href=\"UTD.htm?1/16/1292\">",
"       table 2",
"      </a>",
"      ). We suggest that CSF be obtained when empiric antibiotics are prescribed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lumbar puncture'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H311147\">",
"       '61 to 90 days'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with an abnormal urinalysis should be treated for urinary tract infection. (See",
"      <a class=\"local\" href=\"#H311147\">",
"       '61 to 90 days'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month\", section on 'Overview'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/1\">",
"      Baker MD, Avner JR, Bell LM. Failure of infant observation scales in detecting serious illness in febrile, 4- to 8-week-old infants. Pediatrics 1990; 85:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/2\">",
"      DeAngelis C, Joffe A, Wilson M, Willis E. Iatrogenic risks and financial costs of hospitalizing febrile infants. Am J Dis Child 1983; 137:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/3\">",
"      Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med 2000; 36:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/4\">",
"      Mower WR, Sachs C, Nicklin EL, Baraff LJ. Pulse oximetry as a fifth pediatric vital sign. Pediatrics 1997; 99:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/5\">",
"      Walsh-Kelly C, Nelson DB, Smith DS, et al. Clinical predictors of bacterial versus aseptic meningitis in childhood. Ann Emerg Med 1992; 21:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/6\">",
"      Dagan R, Sofer S, Phillip M, Shachak E. Ambulatory care of febrile infants younger than 2 months of age classified as being at low risk for having serious bacterial infections. J Pediatr 1988; 112:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/7\">",
"      Anbar RD, Richardson-de Corral V, O'Malley PJ. Difficulties in universal application of criteria identifying infants at low risk for serious bacterial infection. J Pediatr 1986; 109:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/8\">",
"      Baker MD, Bell LM, Avner JR. Outpatient management without antibiotics of fever in selected infants. N Engl J Med 1993; 329:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/9\">",
"      Baskin MN, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. J Pediatr 1992; 120:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/10\">",
"      Baker MD, Bell LM, Avner JR. The efficacy of routine outpatient management without antibiotics of fever in selected infants. Pediatrics 1999; 103:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/11\">",
"      Jaskiewicz JA, McCarthy CA, Richardson AC, et al. Febrile infants at low risk for serious bacterial infection--an appraisal of the Rochester criteria and implications for management. Febrile Infant Collaborative Study Group. Pediatrics 1994; 94:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/12\">",
"      Dagan R, Powell KR, Hall CB, Menegus MA. Identification of infants unlikely to have serious bacterial infection although hospitalized for suspected sepsis. J Pediatr 1985; 107:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/13\">",
"      Broner CW, Polk SA, Sherman JM. Febrile infants less than eight weeks old. Predictors of infection. Clin Pediatr (Phila) 1990; 29:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/14\">",
"      Chiu CH, Lin TY, Bullard MJ. Identification of febrile neonates unlikely to have bacterial infections. Pediatr Infect Dis J 1997; 16:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/15\">",
"      Crain EF, Gershel JC. Which febrile infants younger than two weeks of age are likely to have sepsis? A pilot study. Pediatr Infect Dis J 1988; 7:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/16\">",
"      Bonsu BK, Chb M, Harper MB. Identifying febrile young infants with bacteremia: is the peripheral white blood cell count an accurate screen? Ann Emerg Med 2003; 42:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/17\">",
"      Bonsu BK, Harper MB. Utility of the peripheral blood white blood cell count for identifying sick young infants who need lumbar puncture. Ann Emerg Med 2003; 41:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/18\">",
"      Gomez B, Bressan S, Mintegi S, et al. Diagnostic value of procalcitonin in well-appearing young febrile infants. Pediatrics 2012; 130:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/19\">",
"      Bressan S, Gomez B, Mintegi S, et al. Diagnostic performance of the lab-score in predicting severe and invasive bacterial infections in well-appearing young febrile infants. Pediatr Infect Dis J 2012; 31:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/20\">",
"      Maniaci V, Dauber A, Weiss S, et al. Procalcitonin in young febrile infants for the detection of serious bacterial infections. Pediatrics 2008; 122:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/21\">",
"      Dauber A, Weiss S, Maniaci V, et al. Procalcitonin levels in febrile infants after recent immunization. Pediatrics 2008; 122:e1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/22\">",
"      Tan TQ. Procalcitonin in young febrile infants for the detection of serious bacterial infections: is this the \"holy grail\"? Pediatrics 2008; 122:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/23\">",
"      Pantell RH, Newman TB, Bernzweig J, et al. Management and outcomes of care of fever in early infancy. JAMA 2004; 291:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/24\">",
"      Zorc JJ, Levine DA, Platt SL, et al. Clinical and demographic factors associated with urinary tract infection in young febrile infants. Pediatrics 2005; 116:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/25\">",
"      American College of Emergency Physicians Clinical Policies Committee, American College of Emergency Physicians Clinical Policies Subcommittee on Pediatric Fever. Clinical policy for children younger than three years presenting to the emergency department with fever. Ann Emerg Med 2003; 42:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/26\">",
"      Hoberman A, Wald ER, Reynolds EA, et al. Is urine culture necessary to rule out urinary tract infection in young febrile children? Pediatr Infect Dis J 1996; 15:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/27\">",
"      Bramson RT, Meyer TL, Silbiger ML, et al. The futility of the chest radiograph in the febrile infant without respiratory symptoms. Pediatrics 1993; 92:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/28\">",
"      Correa AG. Diagnostic approach to pneumonia in children. Semin Respir Infect 1996; 11:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/29\">",
"      Byington CL, Reynolds CC, Korgenski K, et al. Costs and infant outcomes after implementation of a care process model for febrile infants. Pediatrics 2012; 130:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/30\">",
"      Pantell RH. Febrile infants: aligning science, guidelines, and cost reduction with quality of individualized care. Pediatrics 2012; 130:e199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/31\">",
"      Kadish HA, Loveridge B, Tobey J, et al. Applying outpatient protocols in febrile infants 1-28 days of age: can the threshold be lowered? Clin Pediatr (Phila) 2000; 39:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/32\">",
"      Ferrera PC, Bartfield JM, Snyder HS. Neonatal fever: utility of the Rochester criteria in determining low risk for serious bacterial infections. Am J Emerg Med 1997; 15:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/33\">",
"      Ishimine P. Fever without source in children 0 to 36 months of age. Pediatr Clin North Am 2006; 53:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/34\">",
"      Larsen JW, Sever JL. Group B Streptococcus and pregnancy: a review. Am J Obstet Gynecol 2008; 198:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/35\">",
"      Byington CL, Rittichier KK, Bassett KE, et al. Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens. Pediatrics 2003; 111:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/36\">",
"      Sadow KB, Derr R, Teach SJ. Bacterial infections in infants 60 days and younger: epidemiology, resistance, and implications for treatment. Arch Pediatr Adolesc Med 1999; 153:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/37\">",
"      Greenhow TL, Hung YY, Herz AM. Changing epidemiology of bacteremia in infants aged 1 week to 3 months. Pediatrics 2012; 129:e590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/38\">",
"      Bonadio WA, Hennes H, Smith D, et al. Reliability of observation variables in distinguishing infectious outcome of febrile young infants. Pediatr Infect Dis J 1993; 12:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/39\">",
"      Bachur RG, Harper MB. Predictive model for serious bacterial infections among infants younger than 3 months of age. Pediatrics 2001; 108:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/40\">",
"      Crain EF, Bulas D, Bijur PE, Goldman HS. Is a chest radiograph necessary in the evaluation of every febrile infant less than 8 weeks of age? Pediatrics 1991; 88:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/41\">",
"      Hellerstein S. Antibiotic treatment for urinary tract infections in pediatric patients. Minerva Pediatr 2003; 55:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/42\">",
"      Schnadower D, Kuppermann N, Macias CG, et al. Febrile infants with urinary tract infections at very low risk for adverse events and bacteremia. Pediatrics 2010; 126:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/43\">",
"      Dayan PS, Hanson E, Bennett JE, et al. Clinical course of urinary tract infections in infants younger than 60 days of age. Pediatr Emerg Care 2004; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/44\">",
"      Hsiao AL, Chen L, Baker MD. Incidence and predictors of serious bacterial infections among 57- to 180-day-old infants. Pediatrics 2006; 117:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/45\">",
"      McGowan KL, Foster JA, Coffin SE. Outpatient pediatric blood cultures: time to positivity. Pediatrics 2000; 106:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/46\">",
"      Garcia-Prats JA, Cooper TR, Schneider VF, et al. Rapid detection of microorganisms in blood cultures of newborn infants utilizing an automated blood culture system. Pediatrics 2000; 105:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/47\">",
"      Levine DA, Platt SL, Dayan PS, et al. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. Pediatrics 2004; 113:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/48\">",
"      Greenes DS, Harper MB. Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatr Infect Dis J 1999; 18:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/49\">",
"      Krief WI, Levine DA, Platt SL, et al. Influenza virus infection and the risk of serious bacterial infections in young febrile infants. Pediatrics 2009; 124:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/50\">",
"      Byington CL, Enriquez FR, Hoff C, et al. Serious bacterial infections in febrile infants 1 to 90 days old with and without viral infections. Pediatrics 2004; 113:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/51\">",
"      Melendez E, Harper MB. Utility of sepsis evaluation in infants 90 days of age or younger with fever and clinical bronchiolitis. Pediatr Infect Dis J 2003; 22:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/52\">",
"      Antonow JA, Hansen K, McKinstry CA, Byington CL. Sepsis evaluations in hospitalized infants with bronchiolitis. Pediatr Infect Dis J 1998; 17:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/53\">",
"      Bilavsky E, Shouval DS, Yarden-Bilavsky H, et al. A prospective study of the risk for serious bacterial infections in hospitalized febrile infants with or without bronchiolitis. Pediatr Infect Dis J 2008; 27:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/54\">",
"      Titus MO, Wright SW. Prevalence of serious bacterial infections in febrile infants with respiratory syncytial virus infection. Pediatrics 2003; 112:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/55\">",
"      Purcell K, Fergie J. Concurrent serious bacterial infections in 2396 infants and children hospitalized with respiratory syncytial virus lower respiratory tract infections. Arch Pediatr Adolesc Med 2002; 156:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/56\">",
"      Kuppermann N, Bank DE, Walton EA, et al. Risks for bacteremia and urinary tract infections in young febrile children with bronchiolitis. Arch Pediatr Adolesc Med 1997; 151:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/57\">",
"      Purcell K, Fergie J. Concurrent serious bacterial infections in 912 infants and children hospitalized for treatment of respiratory syncytial virus lower respiratory tract infection. Pediatr Infect Dis J 2004; 23:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/58\">",
"      Hall CB, Powell KR, Schnabel KC, et al. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection. J Pediatr 1988; 113:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/59\">",
"      Oray-Schrom P, Phoenix C, St Martin D, Amoateng-Adjepong Y. Sepsis workup in febrile infants 0-90 days of age with respiratory syncytial virus infection. Pediatr Emerg Care 2003; 19:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/60\">",
"      Ralston S, Hill V, Waters A. Occult serious bacterial infection in infants younger than 60 to 90 days with bronchiolitis: a systematic review. Arch Pediatr Adolesc Med 2011; 165:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/61\">",
"      Yarden-Bilavsky H, Ashkenazi-Hoffnung L, Livni G, et al. Month-by-month age analysis of the risk for serious bacterial infections in febrile infants with bronchiolitis. Clin Pediatr (Phila) 2011; 50:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/62\">",
"      Turner D, Leibovitz E, Aran A, et al. Acute otitis media in infants younger than two months of age: microbiology, clinical presentation and therapeutic approach. Pediatr Infect Dis J 2002; 21:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/26/28074/abstract/63\">",
"      Nozicka CA, Hanly JG, Beste DJ, et al. Otitis media in infants aged 0-8 weeks: frequency of associated serious bacterial disease. Pediatr Emerg Care 1999; 15:252.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6072 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28074=[""].join("\n");
var outline_f27_26_28074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LABORATORY TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      WBC count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4040330\">",
"      Blood culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inflammatory mediators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Urine examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Stool examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neonates (0 to 28 days)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Acyclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H310880\">",
"      Ill-appearing infants (29 to 90 days)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H310985\">",
"      Well-appearing infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H311038\">",
"      - 29 to 60 days",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H311147\">",
"      - 61 to 90 days",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Follow-up for outpatient treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Discharge criteria for admitted patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIFFICULT CLINICAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15639137\">",
"      Dry or traumatic lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Patient on antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Concomitant viral infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Influenza",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Otitis media",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Neonates (0 to 28 days)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H311933\">",
"      Ill-appearing infants (29 to 90 days)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H311941\">",
"      Well-appearing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H311948\">",
"      - Infants 29 to 60 days of age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H311955\">",
"      - Infants 61 to 90 days of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6072\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6072|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/25/18845\" title=\"table 1\">",
"      CSF patterns viral meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/16/1292\" title=\"table 2\">",
"      Empiric treatment febrile infant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27674?source=related_link\">",
"      Acute management, imaging, and prognosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=related_link\">",
"      Bronchiolitis in infants and children: Treatment; outcome; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28951?source=related_link\">",
"      Definition and etiology of fever in neonates and infants (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26360?source=related_link\">",
"      Epidemiology and risk factors for urinary tract infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=related_link\">",
"      Fever without a source in children 3 to 36 months of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2552?source=related_link\">",
"      Management of the infant whose mother has received group B streptococcal chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=related_link\">",
"      Neonatal herpes simplex virus infection: Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=related_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40550?source=related_link\">",
"      Strategies for the evaluation of fever in neonates and infants (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=related_link\">",
"      Treatment, prognosis, and prevention of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14264?source=related_link\">",
"      Urinary tract infections in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42886?source=related_link\">",
"      Urine collection techniques in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=related_link\">",
"      Viral meningitis: Clinical features and diagnosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_26_28075="Disorders with stereotypies";
var content_f27_26_28075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders with stereotypies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physiological",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mannerisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pathological",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mental retardation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autism (Kanner's infantile autism, Asperger's syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rett syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Williams syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tardive dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Akathisia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroacanthocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schizophrenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catatonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obsessive-compulsive disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tourette's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Restless legs syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epileptic automatism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychogenic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jankovic, J, Lang, AE. Classification of movement disorders. In: Germano, IM, (Ed), Surgical Treatment of Movement Disorders, The American Association of Neurological Surgeons (AANS), Lebanon, NH, 1998. p.3.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28075=[""].join("\n");
var outline_f27_26_28075=null;
var title_f27_26_28076="Plasma glucose A1C goals age";
var content_f27_26_28076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Plasma blood glucose goal range (mg/dl)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Values by age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Plasma blood glucose goal range (mg/dl)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        A1C",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Rationale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Before meals",
"       </td>",
"       <td class=\"subtitle2\">",
"        Bedtime/overnight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Toddlers and preschoolers (&lt;6 years)",
"       </td>",
"       <td rowspan=\"4\">",
"        100-180",
"       </td>",
"       <td rowspan=\"4\">",
"        110-200",
"       </td>",
"       <td rowspan=\"4\">",
"        &lt;8.5 percent",
"       </td>",
"       <td>",
"        Vulnerability to hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unpredictable dietary intake and physical activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A lower goal (&lt;8 percent) is reasonable if it can be achieved without excessive hypoglycemia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        School age (6-12 years)",
"       </td>",
"       <td rowspan=\"2\">",
"        90-180",
"       </td>",
"       <td rowspan=\"2\">",
"        100-180",
"       </td>",
"       <td rowspan=\"2\">",
"        &lt;8 percent",
"       </td>",
"       <td>",
"        Vulnerability to hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A lower goal (&lt;7.5 percent) is reasonable if it can be achieved without excessive hypoglycemia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Adolescents and young adults (13-19 years)",
"       </td>",
"       <td>",
"        90-130",
"       </td>",
"       <td>",
"        90-150",
"       </td>",
"       <td>",
"        &lt;7.5 percent",
"       </td>",
"       <td>",
"        A lower goal (&lt;7 percent) is reasonable if it can be achieved without excessive hypoglycemia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Key concepts in setting glycemic goals:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        Goals should be individualized and lower goals may be reasonable based on benefit-risk assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        Blood glucose goals should be higher than those listed above in children with frequent hypoglycemia or hypoglycemia unawareness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        Postprandial blood glucose values should be measured when there is a disparity between preprandial blood glucose values and A1C levels, and to help assess glycemia in patients on basal/bolus regimens",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from: Silverstein J, Klingensmith G, Copeland K. Care of Children and Adolescents with Type 1 Diabetes. Diabetes Care 2005; 28:186. Copyright &copy; 2005 The American Diabetes Association. Lower limits for HgbA1C removed based on American Diabetes Association, Standards of Medical Care in Diabetes -- 2011. Diabetes Care 2011; 34 Suppl 1:S11.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28076=[""].join("\n");
var outline_f27_26_28076=null;
var title_f27_26_28077="Sensitivity and specificity of proposed RV imaging criteria ARVC";
var content_f27_26_28077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity of proposed RV imaging criteria for ARVC*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Value",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Echocardiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Major",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        PLAX RVOT (diastole)",
"       </td>",
"       <td>",
"        &ge;32 mm",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Corrected for body size (PLAX/BSA)",
"       </td>",
"       <td>",
"        &ge;19 mm/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        PSAX RVOT (diastole)",
"       </td>",
"       <td>",
"        &ge;36 mm",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Corrected for body size (PSAX/BSA)",
"       </td>",
"       <td>",
"        &ge;21 mm/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Fractional area change",
"       </td>",
"       <td>",
"        &le;33 percent",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Minor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        PLAX RVOT (diastole)",
"       </td>",
"       <td>",
"        &ge;29 mm",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Corrected for body size (PLAX/BSA)",
"       </td>",
"       <td>",
"        &ge;16 to &le;18 mm/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        PSAX RVOT (diastole)",
"       </td>",
"       <td>",
"        &ge;32 mm",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Corrected for body size (PSAX/BSA)",
"       </td>",
"       <td>",
"        &ge;18 to &le;20 mm/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Fractional area change",
"       </td>",
"       <td>",
"        &le;40 percent",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        MRI&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Major",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Ratio of RV end-diastolic volume to BSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Males",
"       </td>",
"       <td>",
"        &ge;110 mL/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Females",
"       </td>",
"       <td>",
"        &ge;100 mL/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        <strong>",
"         or",
"        </strong>",
"        RV ejection fraction",
"       </td>",
"       <td>",
"        &le;40 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Minor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        Ratio of RV end-diastolic volume to BSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Males",
"       </td>",
"       <td>",
"        &ge;100 mL/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Females",
"       </td>",
"       <td>",
"        &ge;90 mL/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        97",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        <strong>",
"         or",
"        </strong>",
"        RV ejection fraction",
"       </td>",
"       <td>",
"        &le;45 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PLAX: parasternal long-axis view; RVOT: RV outflow tract; BSA: body surface area; PSAX: parasternal short-axis view.",
"     <br/>",
"     * All the major and minor criteria listed in this table are in addition to the requirement that regional wall motion abnormalities must also be present.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The sensitivity and specificity for males and females are the same as listed if, in addition to the stated wall motion criteria, there is either abnormal RV size or function or both.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force criteria. Circulation 2010; 121:1533. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28077=[""].join("\n");
var outline_f27_26_28077=null;
var title_f27_26_28078="Prognosis MPI post CABG";
var content_f27_26_28078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Prognosis after CABG is predicted by stress MPI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 200px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 411 patients who underwent coronary artery bypass grafting (CABG) and were followed for a mean of 5.8 years, survival free of death or myocardial infarction was predicted in part by the results of an exercise test with myocardial perfusion imaging (MPI) obtained within two years of surgery. Significant adverse prognostic variables included angina during exercise, three or more abnormal segments on the postexercise perfusion scan (post segs), and the size of the ischemic defect based upon the number of abnormal segments on the perfusion scan.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Miller, TD, Christien, TF, Hodge, DO, et al, J Am Coll Cardiol 1998; 31:848.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28078=[""].join("\n");
var outline_f27_26_28078=null;
var title_f27_26_28079="Exstrophy small bladder";
var content_f27_26_28079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exstrophy of a small bladder in male newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_26_28079=[""].join("\n");
var outline_f27_26_28079=null;
